Podcasts about GlaxoSmithKline

Today on the show we're talking to media lawyer legend Jonathan Coad about what PR folks need to know about the law. Jonathan Coad graduated from Jesus College Cambridge with an MA in law and is one of the UK's highest profile media lawyers.His practice areas are copyright, defamation and privacy. His media clients have included Disney, ITV, Sky, Viacom, MTV, Channel 4, Sony, Huffington Post and Newsweek. He has undertaken reputation management work for corporate clients such as Amazon, Procter & Gamble, Gucci, GlaxoSmithKline and Cambridge University. He has also acted for high-profile business moguls, senior politicians, music, TV, film and sports stars and members of the Royal Family. He's had 30 years experience at the intersection of media and law and today he's going to talk about PR practitioners should know about dealing with the mediaBefore we start, two pieces of good news at PRmoment this week. The first is that the programme for PR Masterclass: AI in PR is now complete. The PR Masterclass series are hybrid events so you can attend either in person or virtually. The event is on July 2nd.Check out the microsite PRMasterclasses.com for all the details including the speaker line-up.Also, the final entry deadline for The Creative Moment Awards is 20th June. You can see all the categories for 2025 at the microsite creativemomentawards.co.Here's a summary of what Jonathan Coad and PRmoment founder Ben Smith discussed:What does the client want when a media crisis kicks off?What is the role of the corporate PR firm and what is the role of a media lawyer in a PR crisis situation?“The key tools for any PR crisis practitioner (in the UK) are The Independent Press Standards Organisation Code and Ofcom. And less important but none the less as (essential) background the law of data protection, defamation and privacy. Those are my work tools.”Why does media regulation play a vital part in crisis response in the UK?Who makes editorial decisions where contentious issues arise?  What are the criteria on which editorial decisions are made? “99 times out of 100 the editor will take the advice of the in-house lawyer.”What are the sources of perceived risk for media owners? The applicable regulation (press/IPSO, broadcast/Ofcom) or the law (privacy/defamation/date protection)?Who creates perceived risk for the media owners? Is the appetite for risk the same across the media?  Should PR folks treat broadcast and press the same?  How should PR folks treat social media crises for their clients? Where can PR folks learn more about PR, journalism and the law, including Jonathan's book, Reputation Matters.

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

This week, on Pioneers and Pathfinders, we're doing something a little different, with a special two-part conversation featuring Justin Ergler and Keith Maziarek, co-hosts of the Off the Clock podcast and board members of the Legal Value Network. Now, you may remember Keith from a previous episode. He's the Director of Pricing and Legal Project Management at Katten Muchin Rosenman. Justin, a veteran of GlaxoSmithKline, now leads his own consulting practice focused on alternative fee arrangements and innovative legal service delivery. In part one of our wide-ranging discussion, we talked about why this is a great time to enter the legal profession, the ongoing frustrations with the pace of change, and how law firms and legal departments are rethinking billing structures.  Read the full transcript of this episode here: https://www.seyfarth.com/dir_docs/podcast_transcripts/Pioneers_KeithMaziarek_JustinErlger_Pt.1.pdf

In this episode of Thriving in Intersectionality, host Lola Adeyemo speaks with Craig DeLarge, a digital healthcare strategist and mental health advocate whose remarkable 45-year career spans pharmaceutical giants, academia, and global leadership. Craig began as a fashion design major before switching to marketing and has subsequently led to an impressive career trajectory through marketing research, advertising, product management, and eventually digital strategy in the pharmaceutical industry at companies like Johnson & Johnson, GlaxoSmithKline, Novo Nordisk, Merck, and Takeda. Parallel to his corporate roles, he maintained a 25-year teaching career across five business schools in the Philadelphia area. In this conversation, Craig shares invaluable insights on career development across cultural boundaries, the transformative power of international experience, and why it's never too late to pursue new opportunities and advanced education. What You'll Learn in This Episode: Why it's never too late to pursue new career opportunities and advanced education How international experience can transform your perspective and challenge unconscious biases The importance of focusing on process and legacy rather than just career outcomes How personal challenges can evolve into professional purpose and advocacy Understanding intersectionality as a source of both challenges and unique strengths Key Career Insights: Age is Just a Number in Career Development Craig completed his first international assignment at 49 and obtained his second graduate degree at 53. His message to younger professionals: "Don't give up... It's not too late if you're called to it, if you surround yourself with the right community, and if you have a vision for yourself and how you want to impact the world." International Experience Transforms Perspective His three years in Singapore challenged his "American Imperial bias" and connected him with the global African diaspora in unexpected ways. For cross-cultural success, Craig advises: maintain a sense of humor about yourself, build community, and be willing to critique your own biases. Focus on Process, Not Just Outcomes "Make sure that whatever outcome you want, you're not forgetting to have fun and to be engaging meaningfully in the process... You have more control over the process of your career than the outcome of your career." Personal Challenges Drive Professional Purpose A family tragedy involving mental health 19 years ago transformed Craig's career focus, leading to his current work combining digital health expertise with mental health advocacy. This demonstrates how our personal journeys can inform and enrich our professional contributions. About Our Guest Craig DeLarge's career includes executive roles at Johnson & Johnson, GlaxoSmithKline, Novo Nordisk, Merck, and Takeda, alongside 25 years as a university professor teaching marketing, communications, leadership, and business ethics. His educational journey includes degrees from Philadelphia University, University of Westminster (UK), and King's College London. Craig's intersectional identity as an African American male from the South raised in the North, along with his roles as husband, father, and grandfather, have shaped his unique perspective on career development and leadership. Connect with Craig DeLarge: LinkedIn Craig DeLarge Connect with Host Lola Adeyemo: LinkedIn Want to Get Involved? Apply to be on the podcast: Application Link Join Immigrants in Corporate Non-Profit Community: Membership | Facebook | Instagram Are you an HR, Culture, or DEI Leader? Email Lola@EQImindset.com to Get Your Workplace Community Employee Resource Groups (ERGs / BRGs) Launched, Leveraged, and Thriving!

As CEO of Porter Novelli, Jillian Janaczek manages talent and operations of the strategic communications company globally, nurturing key client relationships, and driving business growth across Health, Corporate + Brand, Food + Ag + Nutrition, Purpose + Impact, Tech, and Government, as well as strategic services. She is part of OPRG's (Omnicom PR Group's) global leadership team. ​ Before Porter Novelli, Janaczek was President, BCW New York, spearheading the firm's largest market and managing Fortune 500 clients. She sat on BCW's Global Board and was Chair, Client Risk Committee. ​Earlier in her career, Janaczek was Managing Director of Healthcare at Cohn & Wolfe. Her background includes extensive work with prescription medications and Rx to OTC switches. She has worked closely with leading companies such as AbbVie, GlaxoSmithKline, Gilead, Johnson & Johnson, Merck, Novartis and Novo Nordisk, among many others, providing strategic counsel for U.S. and Global programs. She expanded her role with Novartis Pharma AG by working in-house as Global Brand Manager in Basel, Switzerland. ​

In this Episode I compare healthcare costs and outcomes of many western countries. Then I compare Natropathic VS Alopathic medicine, and how that would fit into our current medical framework. Later I talk about Big Pharma lawsuits, and the struggle between profit and well-being. Big Pharma Lawsuits: 2001 - TAP Pharmaceutical Products - Lupron (Puberty Blocker / Cancer Drug) $875 Million - Medicare Fraud, Kickbacks 2004 - Pfizer - Neurontin (Anti Seizeure) $430 Million total - Criminal and Civil - False Claims Act 2014 - $190M again, because they didn't stop! And, another payment of $325M when the lawyers found the scope of the fraud 2007 - Amgen - Aranesp Enbrel, Neulasta (promote red blood vessel production) $612M Civil / $150M Criminal (Promoting off-label uses) 2011 - Merk - Viox (Anti-inflamitory) $950M Civil Settlement (caused heart attacks) 2012 - GlaxoSmithKline - 10 Medications Paxil, Wellbutrin, and Avandia 3 Billiion (1B Crim / 2B Civil) Falseifying Data, Promotion of Pediatric Use 2013 - Johnson & Johnson - Risperdal (antipsychotic) $1.72B Criminal / $485M Criminal (men grew breasts, not good for elderly) 2015 - Takeda - Actos (Diabetes Drug) $2.4B Civil lawsuit (Caused bladder cancer / heart attack / stroke) 2019 - Bayer & J&J - Xarelto (Blood thinner) $775m Civil (Stroke & Death) Then I look at the murder of Brandy Vaughan by Merk, and how she was an effective community organizer. In a Facebook post dated December 4 of 2019, Vaughan asks: "Ever wonder why I speak out against Big Pharma and suffer the major consequences? Because I will fight for my son and humanity and I will educate people on pharmaceutical product dangers until my last breath!” Dec 7th, 2020 Brandy Vaughan was murdered https://learntherisk.org/    

The standard approach of “7 + 3” chemotherapy in acute myeloid leukemia (AML) treatment has been in place for 50 years. But that may soon change, says Maximilian Stahl, MD, a member of the Adult Leukemia Group at the Dana-Farber Cancer Institute in Boston and a member of the faculty at Harvard University. “My prediction is that in 10 years, you will not see much 7 + 3 anymore. Maybe not even 10 years, maybe five years,” he tells Robert A. Figlin, MD, the interim director and Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Stahl describes how targeted therapies such as menin inhibitor revumenib (Revuforj), which was recently approved by the U.S. Food and Drug Administration, are transforming AML care. Although currently indicated for relapsed/refractory disease, trials are exploring frontline use. “Pretty much, if you can think of any combination treatment in your head, that is already an ongoing clinical trial,” Dr. Stahl explains. He outlines how targeted therapies have already changed practice and looks to what advances are likely in the near future. Dr. Stahl reported a consulting or advisory role with the Boston Consulting Group, Clinical Care Options, Curis Oncology, GlaxoSmithKline, Haymarket, Kymera, Novartis, and Sierra Oncology. Dr. Figlin reported various financial relationships.

It's Not The People We Should Platform, It's the Ideas Karel Cast 25-41 There's a petition from Democrats to demand Gavin Newsom stop platforming extreme Right people. And I agree, we don't need to give these people any more oxygen. But to dismiss their ideas, their arguments, or their issues prematurely, at least some of them, may be just too dismissive. For instance. Vaccines. Are they safe, all of them? No. They are not. And I am living proof. My life has almost been ruined by the Shingrix Vaccine from GlaxoSMithKline. And thousands of others as well. But science finds that acceptable for the good of the many. But what if YOU'RE the one? Why release something that could do those things to more than 100 people total? So RFKJr has a point, he's just obtuse and misguided. The Department of Education. We all agree Education in the USA is broken. We charge too much to college kids to go and have an entire bureaucracy setup to handle their loans. We underpay teachers, schools have become shooting galleries. And kids are coming out of the system complete idiots. Something is wrong and reform should start on the federal level. Abolishing isn't the answer, expanding its mandate is but we can all agree, it's broken. Government: There's not one of us that thinks it has ever truly worked well. The post office is a mess, but privatizing isn't the answer. DMV is a mess. Every government agency is overloaded an inefficient and doesn't really serve the people well. But gutting it is not the answer. Repairing, replacing, modernizing and expanding is. Their grievances often mirror those of the other side. The solutions is what we disagree upon. The Karel Cast is heard on all streaming services from Apple Music to iHeart Media, Spotify to Spreaker. The show is Monday through Thursday at 10:30 am Live PST. It can also be seen on TikTok and Instagram. Karel is a history-making broadcaster and entertainer currently in Las Vegas with his little service girl Ember. The Karel Cast is supported by your donations at patreon.com/reallykarel Please watch, like and subscribe to the videos at youtube.com/reallykarel https://youtube.com/live/60cIpKDilrg

     Trump's war on free speech escalates with the "Take It Down Act," a satire-slaying Trojan horse, as he targets the Constitution and Thomas Massie as well     Meanwhile, the CIA's satanic puppet masters arm jihadists to butcher Christians in Syria they supported with A-10 Warthogs inter alia     Enter Unreal Milk, a lab-grown climate con blessed by Trump's USDA cronies and Bill Gates' millions—no cows, all control!     The elder-killing scandal: midazolam and morphine as chemical executioners, courtesy of Hancock's stockpiles.     Peter McCullough's bird flu grift collapses under scrutiny, but real heroes—like a West Texas doc defying BigPharma & MMR's—shine through NBC's smear campaign.2:30 Trump Wants Massey Gone, Constitution Next, and Satire Outlawed“Continuing Resolution” is an oxymoron.  They CONTINUE to kick the can down the road expecting something different because they have no RESOLUTION, simply feckless cowards.  But the manufactured outrage is NOT about the CR or budget — just like the Canadian tariffs are NOT about fentanyl.  Meanwhile, Trump pushes the “Take It Down Act”, a trojan horse anti-speech bill to outlaw satire.  Heres how it could be fixed — but won't be fixed. 15:45 The Importance of Constitutional Government VS Trump Ego-nomicsA much needed lesson for our time. 25:59 The Who & Why  Behind Trump's Attack on Massie Promises Bought, Promises Paid — BOUGHT & PAID It's easy to see…follow the money.  42:07 Trump Violates Due Process & Law to Follow His Masters: ADL & GreenblattIsrael's shadowy influence looms large. Is this anti-Semitism or anti-Netanyahu-ism? 57:10 CIA's Satanic Shadow Government Unleashes Jihadist Hell: Christians ButcheredFrom Afghanistan to Syria, they've armed bloodthirsty jihadists—like the Al-Qaeda poster child now slaughtering thousands in Latakia—with A-10 Warthogs and heavy weapons, all to topple Assad and install a terrorist worse than ever. Door-to-door executions, women paraded naked and shot, kids forced to kill their families—these U.S.-backed monsters proudly post their atrocities online, screaming "Allah Akbar" over bleeding corpses. Meanwhile, geospatial intel tracks your every move, building AI lifelogs to hunt you by faith and politics 1:19:54 MegaChurch Sued Over “Money-Back Guarantee” on Tithing Are you suing for more when you're already rich in wonders? 1:22:27 Miracles or “Intentional Blindness”? Wake Up to the Divine Spectacle You're Ignoring Every Day!Life wouldn't be a bore, or a chore, if we lived with childlike curiosity to see the miracles permeating in our lives.  Be aware of “intentional blindness”.1:35:57 Trump's Censorship Bombshell: Take It Down Act Unleashes a Speech-Stealing Tyranny!Billed as a shield against nonconsensual deep fakes it will let the powerful zap satire, memes, and criticism with zero proof—just accusations!  With vague terms, no recourse, and tech giants caving to avoid feds, it's civil asset forfeiture for your words!1:50:15 Trump Lists 60 More Elite Universities to Have Grants Removed$400 MILLION from Columbia to start — except for the wrong reasons.  Why was the anti-Americanism of these Marxist universities ignored for decades and funding ONLY CUT for anti-semitism?  It shows what we can expect from a rebranding Dept of Education2:06:51 Will the New CDC Head Look at Vaccine-Autism Connection?Dave Weldon, a vaccine-autism crusader from Vaxxed fame, steps into the ring today for a confirmation showdown—will he strike a Faustian bargain with Senator Cassidy like RFK Jr. did?2:12:02 “UnReal Milk”: Lab-Grown Dairy for the Climate Con GameHailed by Forbes as a climate-saving marvel, this Boston-born Franken-dairy is a “solution” for a non-problem. But wait—who's in charge? The USDA, meant for farm-fresh fare, bizarrely claims jurisdiction over this petri-dish potion, while the FDA sits on the sidelines. Critics cry foul: no cows, no agriculture—yet Trump's crew, including Brooke Rollins, rubber-stamps it alongside mRNA jabs for livestock! Bill Gates and Israel fuel the frenzy, pumping millions into this “no-milk milk” to dodge methane-farting cows. It's an unreal saga that reeks of the climate MacGuffin BS2:30:41 Chemical Restraints Exposed: Midazolam & Morphine Used to Kill the Elderly During “Covid”A shocking revelation that'll turn your stomach!  Matt Hancock's UK midazolam stockpile and GlaxoSmithKline's Irish vaccine agenda hint at a sinister elder-cleansing scheme—pension relief by lethal injection 2:41:39 Peter McCullough's Bird Flu Grift Unravels He can't even make a coherent argument for his “lab leak” nonsense.  And other people are starting to point out his grift.  It's Alex Jones 2.0, spinning half-truths into a fear-fest to sell product.    But there are REAL wins with REAL doctors who have REAL character—like the West Texas family physician who's ditching vaccines.  NBC attacks him for their BigPharma masters but in doing so, they prove his point 2;57:37 What Happens to Gold When the Stock Market Drops by 10% or More?Historical data looks good for gold bugsIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTFor 10% off supplements and books, go to RNCstore.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

     Trump's war on free speech escalates with the "Take It Down Act," a satire-slaying Trojan horse, as he targets the Constitution and Thomas Massie as well     Meanwhile, the CIA's satanic puppet masters arm jihadists to butcher Christians in Syria they supported with A-10 Warthogs inter alia     Enter Unreal Milk, a lab-grown climate con blessed by Trump's USDA cronies and Bill Gates' millions—no cows, all control!     The elder-killing scandal: midazolam and morphine as chemical executioners, courtesy of Hancock's stockpiles.     Peter McCullough's bird flu grift collapses under scrutiny, but real heroes—like a West Texas doc defying BigPharma & MMR's—shine through NBC's smear campaign.2:30 Trump Wants Massey Gone, Constitution Next, and Satire Outlawed“Continuing Resolution” is an oxymoron.  They CONTINUE to kick the can down the road expecting something different because they have no RESOLUTION, simply feckless cowards.  But the manufactured outrage is NOT about the CR or budget — just like the Canadian tariffs are NOT about fentanyl.  Meanwhile, Trump pushes the “Take It Down Act”, a trojan horse anti-speech bill to outlaw satire.  Heres how it could be fixed — but won't be fixed. 15:45 The Importance of Constitutional Government VS Trump Ego-nomicsA much needed lesson for our time. 25:59 The Who & Why  Behind Trump's Attack on Massie Promises Bought, Promises Paid — BOUGHT & PAID It's easy to see…follow the money.  42:07 Trump Violates Due Process & Law to Follow His Masters: ADL & GreenblattIsrael's shadowy influence looms large. Is this anti-Semitism or anti-Netanyahu-ism? 57:10 CIA's Satanic Shadow Government Unleashes Jihadist Hell: Christians ButcheredFrom Afghanistan to Syria, they've armed bloodthirsty jihadists—like the Al-Qaeda poster child now slaughtering thousands in Latakia—with A-10 Warthogs and heavy weapons, all to topple Assad and install a terrorist worse than ever. Door-to-door executions, women paraded naked and shot, kids forced to kill their families—these U.S.-backed monsters proudly post their atrocities online, screaming "Allah Akbar" over bleeding corpses. Meanwhile, geospatial intel tracks your every move, building AI lifelogs to hunt you by faith and politics 1:19:54 MegaChurch Sued Over “Money-Back Guarantee” on Tithing Are you suing for more when you're already rich in wonders? 1:22:27 Miracles or “Intentional Blindness”? Wake Up to the Divine Spectacle You're Ignoring Every Day!Life wouldn't be a bore, or a chore, if we lived with childlike curiosity to see the miracles permeating in our lives.  Be aware of “intentional blindness”. 1:35:57 Trump's Censorship Bombshell: Take It Down Act Unleashes a Speech-Stealing Tyranny!Billed as a shield against nonconsensual deep fakes it will let the powerful zap satire, memes, and criticism with zero proof—just accusations!  With vague terms, no recourse, and tech giants caving to avoid feds, it's civil asset forfeiture for your words! 1:50:15 Trump Lists 60 More Elite Universities to Have Grants Removed$400 MILLION from Columbia to start — except for the wrong reasons.  Why was the anti-Americanism of these Marxist universities ignored for decades and funding ONLY CUT for anti-semitism?  It shows what we can expect from a rebranding Dept of Education 2:06:51 Will the New CDC Head Look at Vaccine-Autism Connection?Dave Weldon, a vaccine-autism crusader from Vaxxed fame, steps into the ring today for a confirmation showdown—will he strike a Faustian bargain with Senator Cassidy like RFK Jr. did?2:12:02 “UnReal Milk”: Lab-Grown Dairy for the Climate Con GameHailed by Forbes as a climate-saving marvel, this Boston-born Franken-dairy is a “solution” for a non-problem. But wait—who's in charge? The USDA, meant for farm-fresh fare, bizarrely claims jurisdiction over this petri-dish potion, while the FDA sits on the sidelines. Critics cry foul: no cows, no agriculture—yet Trump's crew, including Brooke Rollins, rubber-stamps it alongside mRNA jabs for livestock! Bill Gates and Israel fuel the frenzy, pumping millions into this “no-milk milk” to dodge methane-farting cows. It's an unreal saga that reeks of the climate MacGuffin BS2:30:41 Chemical Restraints Exposed: Midazolam & Morphine Used to Kill the Elderly During “Covid”A shocking revelation that'll turn your stomach!  Matt Hancock's UK midazolam stockpile and GlaxoSmithKline's Irish vaccine agenda hint at a sinister elder-cleansing scheme—pension relief by lethal injection 2:41:39 Peter McCullough's Bird Flu Grift Unravels He can't even make a coherent argument for his “lab leak” nonsense.  And other people are starting to point out his grift.  It's Alex Jones 2.0, spinning half-truths into a fear-fest to sell product.    But there are REAL wins with REAL doctors who have REAL character—like the West Texas family physician who's ditching vaccines.  NBC attacks him for their BigPharma masters but in doing so, they prove his point 2;57:37 What Happens to Gold When the Stock Market Drops by 10% or More?Historical data looks good for gold bugsIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTFor 10% off supplements and books, go to RNCstore.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In this episode of The Rob & Jai Show, Dr. Rob Rothman and Dr. Jai Parekh host a captivating conversation with Andrew Stewart and Anthony Wallace—two leaders who are among the most experienced and admired executives in ophthalmology. Andrew Stewart, with over 25 years of pharmaceutical leadership across Bausch + Lomb, AbbVie, and Allergan, shares how his global business acumen shapes innovation in eye care. Anthony Wallace, a 26-year healthcare veteran with leadership roles at Novartis, Merck, and GlaxoSmithKline, reflects on leading Bausch + Lomb's U.S. Surgical business and his passion for patient-centered solutions. Both leaders bring a wealth of knowledge, relatable stories, and a shared commitment to advancing ophthalmic care.In this episode, you'll learn:

American culture is everywhere, shaping everything from entertainment to fast food—but could its most profound influence be something far more unsettling? Across the globe, from Hong Kong to Japan, Western mental health concepts are spreading, often replacing traditional ways of understanding distress. Depression, PTSD, and eating disorders are appearing in regions where they were once rare, raising the question: is this organic, or is something more deliberate at play? In this episode, we dive into the unsettling case from Japan, where pharmaceutical giant GlaxoSmithKline saw an untapped market for antidepressants and set out to change the nation's perception of sadness itself. Through marketing, media manipulation, and cultural rebranding, they turned “feeling down” into a medical condition overnight—selling billions in pills along the way. Could this be an example of a memetic virus, an idea so powerful that it rewires an entire society's approach to mental illness? Then, for our Plus+ members, we uncover reports of bizarre shape-shifting UFOs, eerie green mist that seems to transport people between dimensions, and chilling encounters with dark entities that should have never been summoned. Links Crazy Like Us: The Globalization of the American Psyche Mental illnesses can be acquired via memetic viruses Chris Lakin Blog Anorexia In Hong Kong Dentsu chief to resign over employee's suicide from overwork Plus+ Extension The extension of the show is EXCLUSIVE to Plus+ Members. To join, click HERE. The Case of the Morphing Flying Saucer David Grusch seen at Esalen at Skywatcher UFO summoning event When UFOs Attack - Documented Cases of Hostile Alien Encounters I Experienced Terrifying Visits From A Succubus Yale News Mabel White Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Isabel and Jade for part two of their World Cancer Day special for 2025, where guest Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson, uncovers more of his insights into the oncology space.  In this instalment, Martin shares his thoughts on improving access to innovative cancer medicines, improving public trust toward the industry and his personal leadership style.  A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager. 

Dr. Dan Cohen is the former Chairman of CNS, Incorporated. Dr. Cohen was the driving force behind the meteoric rise of Breathe Right nasal strips, acquiring the rights to manufacture and sell the product for the medical equipment company he founded in 1982. In 2006, GlaxoSmithKline acquired CNS, including its Breathe Right nasal strips and FiberChoice chewable fiber supplement products, for $566 million. Dr. Cohen's training is in neurology at the University of Minnesota and he is a Diplomat of the American Board of Psychiatry and Neurology.  Doctor Cohen also authored the books, Addicted To My Ego and Co-Authored Claim Your Basic Rights.   This Episode is Sponsored By: Jon Ostenson, Founder of FranBridge Consulting and Top 1% US Franchise Consultant is here to help you explore the world of non-food franchising opportunities today. Jon and his team are part of the largest brokerage in the US and have vetted the market thoroughly. Sign up for a free consultation call with Jon today at millionaire-interviews.com/franbridgeconsulting and receive a FREE copy of his new book Non-Food Franchising. Franbridge Consulting offers five more non-food franchise opportunities in 2024 that you can explore. FranBridge is hands down the premier source of the best opportunities in the non-food franchising world. You can hear more of Jon's story and how he started FranBridge Consulting on Episode 250 of our podcast. Sign up for a free consultation call with Jon today at millionaire-interviews.com/franbridgeconsulting and receive a FREE copy of his new book Non-Food Franchising.   Want to Support the Show? Well we'd love for you to join our Patreon Group!  What's in it for you?  Well you'll instantly get a scheduled call from Austin, where he'll help you with your current or future business... Sign-Up Now at millionaire-interviews.com/patreon.

Dr. Daniel Cohen is a Neurologist and serial entrepreneur. He co-founded SOLTEC Health to study the healing effect of magnetic waveforms on sleep and neurodegenerative conditions.SOLTEC Health (https://soltechealth.com/) has developed a safe, non-invasive, drug-free platform technology that can greatly expand the already growing field of neuromodulation. With this new disruptive technology, it is now possible to influence a region of the central nervous system, the brainstem, which includes the autonomic nervous system. The technology addresses the #1 health complaint in the U.S. – POOR SLEEP!Previously, Dr. Cohen co-founded and managed CNS, Inc. until it was acquired by GlaxoSmithKline in 2006 for $566M. CNS, a developer and marketer of hi-tech medical products (brainwave monitors and sleep disorders diagnostic equipment) was best known for its consumer products, the Breathe Right® nasal strip and the FiberChoice™ chewable fiber supplement.Dr. Cohen holds numerous patents related to EEG and sleep analysis algorithms and devices and additional utility patents related to synchronized sound, vibration and electromagnetic fields. Dr. Cohen received his MD from Temple Medical School with high distinction. His training is in Neurology at the University of Minnesota and is a Diplomat of the American Board of Psychiatry and Neurology. SHOWNOTES:

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk's drug Wegovy saw a significant increase in sales in 2024, but analysts are still not satisfied and are questioning why the company can't access more patients, especially in the U.S. Despite this success, there is a lack of female leadership in new biotech companies, with only nine out of 102 launches having a woman at the helm. In other news, GlaxoSmithKline is looking to make deals in the cancer, respiratory, and inflammation sectors, while Valerio is facing financial challenges and has had to cut operations. The biotechnology industry is facing a shift towards more data integration and an increase in mergers and acquisitions.Women leaders in biotech are declining as new company founders prioritize CEOs with a proven track record. Out of the 102 most recent company launches or financings, only nine had a woman at the helm. The lack of women in leadership roles in biopharma continues to be a recurring issue. Biopharma companies are investing more in licensing deals to enrich their pipelines with novel therapies, with a focus on combating patent expirations and generics. Despite challenges, such as a shortage of skilled operators, training programs are being emphasized to upskill teams effectively. Some top biopharma licensing deals of 2024 are highlighted, along with updates on various companies' earnings and strategic moves. The Biotech Sisterhood aims to provide fellowship among women leaders in the industry, showcasing a group of women and allies as their authentic selves at events like the J.P. Morgan Healthcare Conference. Additionally, the newsletter includes job listings and opportunities for industry professionals to stay informed and engaged.

Join Isabel and Jade as they present a special World Cancer Day 2025 edition of the podcast. They are joined by Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson.  In this first instalment of the conversation, Martin and Jade discuss this year's theme ‘United by Unique', the increasing importance of real-world evidence in oncology and improving access to innovative cancer medicines.   A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager.

On this episode, hear the 2024 updates on COVID-19, long COVID and the latest developments in research in rheumatology. Hosted by Dr. Leonard Calabrese. Intro 0:12 In this episode 0:21 Coming up on Healio Rheuminations 0:56 COVID-19, long COVID and the rheumatologist with Leonard Calabrese, DO 2:19 Questions 3:12 Long COVID 4:46 Calabrese's bias 10:15 The evidence 13:08 Auto antibodies 14:54 Why does the body develop auto antibodies? 17:47 COVID-19 and epidemiologic association 22:25 New clinical entity 26:40 Therapeutic implications 31:00 In conclusion 32:00 Thanks for listening 33:18 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

Alexandra C. Melo (PhD) is a Homeopath and Microbiologist (PhD) practicing in London and worldwide online. Following her PhD in King's College London in Applied Microbiology and subsequent Post Doctoral position at Glaxosmithkline she embarked on a quest of finding the optimal approach to health. She has found the Homeopathic approach to be most complete, bringing real and lasting health benefits as it focuses on the cause of disease, rather than just the superficial removal or suppression of symptoms. She loves homeopathy, because it focuses on the study of Nature! Given her academic background, she thoroughly enjoyed embarking on the most incredible learning journey; the healing secrets of the energetic contents of every substance on this planet, everything is a clue, every substance can be curative. There is the structure initiated by the mineral Kingdom, the sensitivity of plants in the Vegetal Kingdom, the competitiveness of the animal Kingdom and the liberation of stuck, deep miasmic states that the nosodes allow. Since she was a child, she always loved children and animals (particularly horses and dogs). Whilst living in Greece became involved with many rescue operations and as a horse lover and rider my interest fell particularly on horses, dogs, amongst other animals. Children's health is one of the most concerning aspects of parenthood. Although homeopathy works well in variety of diseases, it has special affinity for childhood problems. With over a decade of experience working with paediatricians and veterinarians she still finds remarkable to see how people and creatures respond to this wonderful system of medicine Website: https://alexcmelo.com/ Facebook group Farm Animals and Homeopathy: https://www.facebook.com/groups/farmanimalsandhomeopathy Ebook on Homeopathic Aid for Horse Owners and Riders: Homeopathic Aid for Horse Owners & Riders Profile on Homeopathy 24/7: Dr. Alexandra Melo | Practicing Classical Homeopath If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode.

My guest today is Andy Lopata. A professional relationship strategist with notable clients such as PayPal and GlaxoSmithKline. Andy shares his 25-year journey from corporate escapee to a networking expert, emphasizing the shift from 'networking' to 'professional relationship strategy.' He discusses the importance of building, nurturing, and leveraging relationships in the workplace, especially amid the complexities of hybrid working environments. Andy also introduces his concept of a 'blended mindset' to balance strategic and relational networking, highlighting the power of curiosity, authenticity, and vulnerability in building trust. He offers practical insights into overcoming silos in organizations and how strategic relationship building can benefit leaders and teams. Our discussion concludes with Andy's perspective on future workplace trends, particularly around hybrid working and digital communication. Episode Minutes: Minute 4: The Evolution of Networking Minute 8: Building Strategic RelationshipsMinute 12: The Blended Mindset  Minute 31: Future Trends in the Workplace To find out more about my work, please visit Dana Williams Consulting. LinkedIn Instagram Email: hello@danawilliamsco.com Journal your way to a life with purpose. The Strengths Journal™ is the first and only Gallup-certified daily planner that helps you actively use your strengths to dominate each day and ultimately– transform your life.

In this episode, Dr. Kenneth Lyons Jones, one of the pioneers who first identified Fetal Alcohol Spectrum Disorders (FASD) in the United States in 1973, and Dr. Christina Chambers, a renowned epidemiologist who has conducted groundbreaking research on the prevalence of FASD, join host Chris Stallman, CGC, to discuss the discovery of FASD, its common physical and cognitive traits, and its prevalence today. BONUS: Earn continuing education credits for listening to our entire FASD 3-part series. Scroll down to learn more. Resources Mentioned in This Episode: Dr. Kenneth Lyons Jones on the History of Fetal Alcohol Syndrome - FASD  Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities | Antenatal Exposures and Child Outcomes | JAMA | JAMA Network  Fetal Alcohol Spectrum Disorders – American Academy of Pediatrics Types of Treatment for FASDs | Fetal Alcohol Spectrum Disorders | CDC Choline supplements in young children with fetal alcohol spectrum disorder have lasting cognitive benefits | National Institute on Alcohol Abuse and Alcoholism (NIAAA)  _______________________________________________________________________________________________________ MotherToBaby: FASD Podcast SCPD4929     PROGRAM DESCRIPTION: This podcast series is intended to reach various audiences, including healthcare professionals, who can use the information presented to inform their practice and their interaction with clients/patients. The podcast episodes will educate participants on 1) the discovery, prevalence, and newest research on the topic of fetal alcohol spectrum disorders (FASDs), 2) CDC's work in addressing prenatal alcohol and other substance use and FASDs, and 3) the experiences of people living with FASDs. OBJECTIVES: After completing this course, the learner will be able to: 1.      Describe Fetal Alcohol Spectrum Disorders (FASDs). 2.      Describe the National Center of Birth Defects and Developmental Disabilities' (NCBDDD) approach to addressing FASDs. 3.      Describe the impact on people who are living with FASDs. 4.      Describe how interprofessional collaboration addresses FASDs. 5. Describe how interprofessional teams can help people living with FASDs transition from pediatric to adult healthcare.   FACULTY/                                                   CREDENTIALS: Laura Bousquet, Family Navigator/Self-Advocate, FASD United Christina Chambers, PhD, MPH, Distinguished Professor of Pediatrics, University of California, San Diego Elizabeth Dang, MPH, Behavioral Scientist, Centers for Disease Control and Prevention Nicholas Deputy, PhD, MPH, Health Scientist, Centers for Disease Control and Prevention Kenneth Jones, MD, Distinguished Professor of Pediatrics, University of California, San Diego  Chris Stallman, MLS, MS, CGC, Director,    MotherToBaby Arizona, University of Arizona  Jennifer Wisdahl, Chief Operating Officer, FASD   United   CE ORIGINATION DATE: CE EXPIRATION DATE:   January 9, 2025 January 9, 2027     URL   https://momtobaby.org/FASDep81youtube   INTENDED AUDIENCE:   Advanced Practice Nurses, Certified Health Educators, Medical Assistants, Licensed Practical/Vocational Nurses, Physicians, Physician Assistants, Registered Nurses, and Social Workers   PREREQUISITES:   Learners will have a basic understanding of what fetal alcohol spectrum disorders are.   FORMAT: This activity is Web on Demand   CONTACT INFORMATION: CDC's CE Accreditation Team has a policy for grievances that is available upon request.   Division of Birth Defects and Infant Disorders cdcinfo@cdc.gov    ACCREDITATION STATEMENTS:     In support of improving patient care, this activity has been planned and implemented by the Centers for Disease Control and Prevention and MotherToBaby. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team   CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CNE: The Centers for Disease Control and Prevention designates this activity for 0.5 nursing contact hours. CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program. CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 0.5. CDC provider number 98614. DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.    CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Dr. Christina Chambers, PhD, MPH and she wishes to disclose she receives research funding from Amgen, AstraZeneca, GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer, Inc., Regeneron, Hoffman La-Roche-Genentech, Genzyme Sanofi-Aventis, Takeda Pharmaceutical Company Limited, Sanofi, UCB Pharma, USA, Leo Pharma, Sun Pharma Global FZE, Gilead, Novartis, and the Gerber Foundation.  All relevant financial relationships listed for this individual have been mitigated. Content will not include any discussion of the unlabeled use of a product or a product under investigational use. CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity. The Centers for Disease Control and Prevention (CDC) complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex (including pregnancy, sexual orientation, and gender identity). To learn more visit: https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html. Instructions for Obtaining Continuing Education (CE) To receive continuing education (CE) for SCPD4929 – MotherToBaby: FASD Podcast, please visit CDC TRAIN and search for the course in the Course Catalog using SCPD4929 Follow the steps below by January 9, 2027. Register for and complete the course. Pass the post-assessment at 75 %. Complete the evaluation. Visit Your Learning to access your certificates and transcript.   FEES: No fees are charged for CDC's CE activities.   ______________________________________________________________________ Looking for even more education about FASD? Don't miss a special free Birth Defects Awareness Month webinar January 31, 2025 at 9a PT/12p ET. The webinar will be presented by Dr. Noemi Spinazzi of the American Academy of Pediatrics. It is a free webinar, but advanced registration is required at the following link: https://momtobaby.org/FASDwebinar2025

                                              About Myrto Legaki Myrto Legaki is a Leadership and Corporate Wellbeing Consultant, Keynote Speaker and founder of One Breath Mindfulness Center. She collaborates with major organizations around the world such as AbbVie, Novartis, Microsoft, Google, Roche, GlaxoSmithKline, MSD, Phillip Morris, and Nestlé, empowering leaders, executives, and teams in unlocking their full potential through leadership trainings that integrate neuroscience, psychology, and mindfulness techniques. With 15 years of experience as a management consultant and marketing manager in New York, London, and Athens leading diverse teams in high-performance environments, Myrto brings a wealth of practical insight to her work. A sought-after speaker around the world, Myrto delivers engaging keynotes and workshops on core leadership skills, wellbeing, mental health, diversity and inclusion, and mindfulness. She is a certified mindfulness and MBSR trainer from the University of Massachusetts and Brown University and a systemic psychotherapist in training at the Athenian Institute of Anthropos (AKMA). Her academic background includes an MSc degree in Finance from the University of Piraeus and an MBA in Leadership and Communications from Boston University Episode Notes 06:54 Lesson 1: Own your journey, or someone else will 11:33 Lesson 2: Seek out the sages 15:05 Lesson 3: Try again, fail again, fail better 16:56 Lesson 4: Your lens shapes your world 21:04 Lesson 5: Always be building bridges 24:35 Affiliate Break 25:06 Lesson 6: Change is where the magic happens 28:30 Lesson 7: Celebrate your wins 31:38 Lesson 8: Treat your body like a temple 33:51 Lesson 9: Listen to the voice inside 36:43 Lesson 10: You are enough

Happy New Year! In our first episode of 2025, Patrick is joined by Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences. Erik is also the formerr Senior Vice President of Target Discovery at GlaxoSmithKline and a former Professor at Stanford and Uppsala universities. Patrick and Erik discuss Wave's world-first discovery in RNA editing therapies for Alpha-1 Antitrypsin Deficiency (AATD), Erik's far-reaching career across academia, big pharma and biotech, and how to be a present parent in the thick of a thriving career.

Our usual guests talk about journeys that they chose to embark on: starting a company, solving a problem, creating opportunities, or navigating life and career. In our current series, we're probing into a trip that none of us opted into but we're all aboard anyway…and that is artificial intelligence. AI influences what we see, hear, buy, and think, how we navigate the world, and how we navigate daily life. In this episode, we talk with Dr. Bob Morais, a business anthropologist and expert in human behavior, particularly in the realm of marketing. Dr. Morais had a 35+ year career in advertising and market research and is a Lecturer at Columbia Business School. Morais digs into how AI is used today, the opportunities and pitfalls, how AI stretches the range of possibilities, AI "hallucinations" and why it's best utilized as a partner and collaborator rather than a substitute. Morais was a Principal/Co-owner of a market research firm and spent years with advertising agencies rising to the role of Chief Strategic Officer. He has worked with Coca Cola, Danone, GlaxoSmithKline, Johnson & Johnson, Post Foods, Proctor & Gamble, Safeway, WD-40, Fairmont, Raffles, and Swissôtel, and many others. His books include Advertising and Anthropology; Ethics in the Anthropology of Business; and The Language of Branding. His articles have appeared in Forbes, Advertising Age, Huffington Post, American Anthropologist, Human Organization, Culture and Organization, and Medium. Find all of our prior episodes at whatiwishiknewshow.com We welcome your questions and ideas. Send us at email at hello@whatiwishiknewshow.com

Is quantum computing the next big thing? This week, Autonomous Technology and Robotics Director of Research Sam Korus and Associate Portfolio Manager Nick Grous are joined by ARK Chief Futurist Brett Winton to discuss the latest advancements in quantum computing and AI drug discovery. They discuss Google's recent quantum chip announcement, the challenges of scaling quantum technology, and the potential applications in drug discovery. The conversation shifts to the partnership between GlaxoSmithKline and Relation Therapeutics, highlighting the promise of AI in revolutionizing drug development processes, reducing costs, and improving efficiency. The episode concludes with insights on the future of drug development and the potential for significant market changes in the pharmaceutical industry.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn't mean we don't have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we're sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com. Tune in every week as we react to the latest in innovation. Here and there we'll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK's quick takes on what's going on in tech today.Key Points From This Episode:Quantum computing is still 15 years away from commercial viability.AI is transforming drug discovery, making it faster and cheaper.AI drug discovery could reduce development costs to $600 million.The future of healthcare may focus on curing diseases rather than just treating them.For more updates on Public.com:Website: https://public.com/YouTube: @publicinvestTwitter: https://twitter.com/public

Highlights:

This 30-minute CME-accredited program, hosted by John Kuruvilla, MD, discusses best practices for talking to patients with hematologic malignancies about possibly participating in clinical trials.Jointly Provided by American Academy of CME and CheckRare CE.Support for this accredited continuing education activity has been made possible through educational grant from Merck.Estimated time to complete: 0.5 hours Start date: November 30, 2024End date: November 30, 2025  Activity FacultyJohn Kuruvilla, MDHematologist / Clinical InvestigatorPrincess Margaret Cancer CentreProfessor of MedicineUniversity of Toronto Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hematology-oncology. Other healthcare providers, including NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able to- Describe the importance of clinical trials in furthering the science of hematologic malignancies treatment.- Describe and utilize best practices for engaging patients in shared decision making regarding clinical trial participation. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows: Faculty Educator/PlannerDr. Kuruvilla discloses the following relevant financial relationships with ineligible companies:Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Beigene, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle GeneticsConsultant: AbbVie, Bristol Myers Squibb, Gilead Sciences/Kite, Merck, Roche, Seattle GeneticsGrant/Research Support: AstraZeneca, Kite, Merck, Novartis, RocheData Safety Monitoring Board: KaryopharmPlanners for this activity have no relevant financial relationships with any ineligible companies. This activity will not review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please go to https://checkrare.com/learning/p-hematologic-malignancies-and-clinical-trial-participation-a-shared-decision-making-approach/   PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org               

Dr. Linda Duska and Dr. Domenica Lorusso discuss the practice-changing results of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which evaluated pembrolizumab plus chemoradiotherapy as treatment for previously untreated, high-risk, locally advanced cervical cancer. TRANSCRIPT  Dr. Linda Duska: Hello, I'm Linda Duska, your guest host of the ASCO Daily News Podcast today. I'm a professor of obstetrics and gynecology and serve as the associate dean for clinical research at the University of Virginia School of Medicine. On today's episode, we'll be discussing a new standard of care for previously untreated, high- risk locally advanced cervical cancer. This follows the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which I will be referring to as KEYNOTE-A18 for the rest of this podcast, which demonstrated that pembrolizumab plus chemoradiotherapy improved both progression-free and overall survival compared to chemoradiotherapy alone. I was a co-author of this study, and I'm delighted to be joined today by the study's lead investigator, Dr. Domenica Lorusso, for today's discussion. She is also a professor of obstetrics and gynecology. She's at Humanitas University Rosano and the director of the Gynecologic Oncology Unit at the Humanitas Hospital San Pio in Milan, Italy. Our full disclosures are available in the transcript of this episode. Dr. Lorusso, it's great to be speaking with you today. Dr. Domenica Lorusso: Thank you, Linda. It's a great pleasure to be here. Thank you. Dr. Linda Duska: So I was hoping you could start us out with some context on the challenges associated with treating patients with high-risk, locally advanced cervical cancer. Dr. Domenica Lorusso: Yes. I have to make a disclosure because in my experience as a gynecologist, cervical cancer patients are the most difficult patients to treat. This is a tumor that involves young patients [who often have] small kids. This is a very symptomatic tumor. More than 50% of patients report pain. Sometimes the pain is difficult to control because there is an infiltration of the pelvic nerves and also a kind of vaginal discharge, so it's very difficult to treat the tumor. Since more than 25 years, we have the publication of 5 randomized trials that demonstrate that when we combine platinum chemotherapy to radiation treatment, we increase overall survival by 6%. This is the new standard of care – concurrent chemoradiation plus brachytherapy. This is a good standard of care because particularly modern, image-guided radiotherapy has reported to increase local control. And local control in cervical cancer translates to better overall survival. So modern radiotherapy actually is able to cure about 75% of patients. This is what we expect with chemoradiation right now. Dr. Linda Duska: So what are the key takeaways of A18? This is a really exciting trial, and you've presented it a couple of times. Tell us what are the key takeaways that you want our listeners to know. Dr. Domenica Lorusso: Linda, this is our trial. This is a trial that we did together. And you gave me the inspiration because you were running a randomized phase 2 trial exploring if the combination of pembrolizumab to concurrent chemoradiation was able to give signals of efficacy, but also was feasible in terms of toxicity. There were several clinical data suggesting that when we combine immunotherapy to radiotherapy, we can potentially increase the benefit of radiotherapy because there is a kind of synergistic effect between the two strategies. Radiotherapy works as a primer and immunotherapy works better. And you demonstrated that it was feasible to combine immunotherapy to concurrent chemoradiation. And KEYNOTE-A18 was based on this preliminary data. We randomized about 1,060 patients to receive concurrent chemoradiation and brachytherapy or concurrent chemoradiation and brachytherapy in combination with pembrolizumab followed by pembrolizumab for about two years. Why two years? Because in more than 80% of cases, recurrence in this patient population occurred during the first two years. So the duration of treatment was based on the idea to provide protection to the patient during the maximum time of risk. And the trial had the two primary endpoints, progression free and overall survival, and met both the endpoints, a significant 30% reduction in the risk of progression that was confirmed. At the 3-year follow up, the observation was even better, 0.68. So 32% reduction in the risk of progression. And more importantly, because this is a curative setting, 33% reduction in the risk of death was reported in the experimental arm when pembro was combined with chemoradiation. Dr. Linda Duska: That's amazing. I wanted to ask you, a prior similar study called CALLA was negative. Why do you think A18 was positive? Dr. Domenica Lorusso: Linda, there are several discussions about that. I had the possibility to discuss several times with the PI of CALLA, Brad Monk. The idea of Brad is that CALLA was negative because of using durvalumab instead of PD-1 inhibitor, which is pembrolizumab. I do not have exactly the same impression. My idea is that it's the kind of patient population enrolled. The patient population enrolled in KEYNOTE-A18 was really a high-risk population; 85% of that patient were node positive, where the definition of node positivity was at least 2 lymph nodes in the pelvis with a short diameter of 1.5. So, we are very confident this patient was node-positive, 55% at the grade 3 and 4 diseases. So this is really a high-risk population. I remember at the first presentation of CALLA, I was honored to discuss the CALLA trial when it was first presented at IGCS a few years ago. And when I received the forest plot of Calla, it was evident to me that in patients with stage III and node positive there was a signal of efficacy. And we have a huge number of patients with node positive. So in my opinion this is the reason why KEYNOTE-A18 is positive. Dr. Linda Duska: Yeah, I agree with you. I've thought about it a lot and I think you're right about that. The INTERLACE trial results were recently published. How should we interpret these results in the context of A18? Dr. Domenica Lorusso: So it's very difficult to compare the 2 trials. First of all, in terms of population. The population enrolled in INTERLACE is a low-risk, locally advanced but low risk population; 76% were stage II, 10% were stage I, 60% were node-negative patients. So, first of all, the population is completely different. Second is the type of radiotherapy that was provided. INTERLACE is a 10-year long trial, but in 10 years the quality and the technique of radiotherapy completely changed. Only 30% of patients in INTERLACE received what we call the modern image-guided brachytherapy, which is important because it provides local control and local control increases overall survival. And third, we read the paper. I'm not a methodologist, but there are some methodological biases in the paper. All the statistical design of the trial was based on PFS, but PFS was evaluated at physician description. And honestly, I never saw a trial that had no pre-specified timeline for radiological evaluation. It's very difficult to evaluate progression in cervical cancer because the fibrosis related to radiotherapy changes the anatomy in the pelvis. And I think that the radiological evaluation is important to address if the patient is progressing or not. Particularly, because the conclusion of CALLA is that the PFS was mainly in favor of distant metastasis. So really, it's difficult for me to understand how distant metastasis may be evaluated with the vagina visit. So really, it's very difficult to compare the two trials, but I have some concerns. And also because of toxicity in the study, unfortunately 30% of patients did not complete concurrent chemoradiation because of residual toxicity due to induction chemotherapy. So I wanted to be sure in the context of modern radiotherapy, if really induction chemo adds something to modern radiotherapy. Dr. Linda Duska: Well, I have two more questions for you. As we move immunotherapy into the front line, at least for these high risk locally advanced cervical cancer patients that were eligible for A18, what does that mean then for hopefully those few that develop recurrence in terms of second line therapy? Dr. Domenica Lorusso: Well, Linda, this is a very important question. We do not have data about immuno after immuno, but I would not completely exclude this hypothesis because in KEYNOTE-A18, the patient received treatment for a well-defined time period. And for those patients not progressing during immunotherapy, I really guess if there is a space for the reintroduction of immunotherapy at the time of recurrence. In this moment we have 30% of patients in KEYNOTE-A18 in the control arm that receive immunotherapy after progression, but still we have 11% of patients that receive immunotherapy in combination with concurrent chemoradiation and then receive, again, immunotherapy in later line of therapy. I think we need to collect these data to capture some signals and for sure we have the new drug. We have antibody drug conjugate. The trials are ongoing exploring the role of antibody drug conjugate, particularly in immune pretreated patients. So I think this is a very interesting strategy. Dr. Linda Duska: I was going to ask you, “What are the next steps,” but I think you already answered that question. You talked about the second line. If you were going to redesign a study in the frontline, what would it look like? Dr. Domenica Lorusso: Probably one question that I would like to answer – there are two questions in my opinion in KEYNOTE-A18 – one is induction immunotherapy. Linda, correct me if I'm wrong, you reported very interesting data about the immune landscape change when you use induction immunotherapy. And I think this is something that we need to explore in the future. And the second question is the duration of maintenance. Because, again, we decided for two years based only on the epidemiology of recurrence, but I guess if one year may be enough. Dr. Linda Duska: I think this sequencing question is really important, that the induction immunotherapy was actually GY017. I can't take credit for that, but I think you're right. I think the sequencing question is really important. Whether you need the concurrent IO or not is an important question. And then to your point about the 2 years, the length of the need for maintenance therapy is a question that we don't know the answer to. So there are lots of really important questions we can continue to ask. I want to thank you so much for sharing your valuable insights with us on the podcast today. You're always so thoughtful about this particular study and cervix cancer in general and also for your great work to advance the care for patients with GYN cancers. Dr. Domenica Lorusso: Thank you, Linda. It's our work - we progress together. Dr. Linda Duska: Yes. And we thank the patients as well. The over 1,000 patients that went on this trial during a pandemic. Right? Dr. Domenica Lorusso: Absolutely. Without their generosity and their trust, we would not be able to do this trial. Dr. Linda Duska: So we're very grateful to them and we thank our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you all.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Linda Duska @Lduska Dr. Domenica Lorusso   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:   Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn Dr. Domenica Lorusso: Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept, Sutro Biopharma, Novartis, Novocure, Daiichi Sankyo/Lilly Speakers' Bureau: AstraZeneca, Clovis, GSK, MSD, ImmunoGen, Seagen Research Funding (Inst.): PharmMar, Clovis, GSK, MSD, AstraZeneca, Clovis Oncology, Genmab, Seagen, Immunogen, Incyte, Roche, Pharma&, Corcept Therapeutics, Alkermes Travel, Accommodations, Expenses: AstraZeneca, Clovis, GSK, Menarini  

The future of biology. In it we cover machines controlling cells, manipulating biology with light, algorithms for drug development, and how biotech is becoming a low cost and mass production industry. Deniz Kent is CEO of Prolific Machines. Prolific is the first biotech company to harness light as a more efficient way to produce lab grown food, life saving drugs, and novel biosolutions. Offering a full stack tool kit from bioreactor to AI-software, Prolific's groundbreaking technology provides dynamic control over virtually any cell function in any cell type. Until now, biomanufacturing has been limited to indirect cell control via expensive, inefficient, and imprecise tools like chemicals. Prolific's platform enables direct control using light to produce new and superior biolsolutions faster, cheaper, and at greater scale. Based in Silicon Valley, the four year old company has raised $87 million in venture capital from the likes of Mayfield, Breakthrough Energy Ventures, In-Q-Tel and Fonterra. Prolific's co-founder and CEO is Dr Deniz Kent, an expert in biological systems who earned his PhD in the Center for Stem Cells and Regenerative Medicine at King's College London. During his studies he co-discovered a new human liver stem cell, worked on cures for Asthma at GlaxoSmithKline and develop research in the field of cancer immunotherapy. Sign up for new podcasts and our newsletter, and email me on danieldarling@focal.vcSee omnystudio.com/listener for privacy information.

Dr. Maame Yaakwah Blay Adjei, a leader in food science and sensory evaluation. She is a Senior Lecturer at the Department of Nutrition and Food Science, University of Ghana, and lead consultant at Sentinel Foods, PAMP Ghana Ltd, Ghana - contributing significantly to food science research and education in Africa.   With over 20 years of experience across both academic and industry sectors, Dr. Maame Yaakwah Blay Adjei has worked in various organizations, including Charles Sturt University in Australia, GlaxoSmithKline, and Leatherhead Food Research, both in the UK.   She believes that what we consume has a profound impact on our overall health and has focused her research and development on sensory evaluation and consumer science. She previously worked at Charles Sturt University as a Lecturer and Subject Coordinator before returning to Ghana to join the University of Ghana.   As a Senior Lecturer at the University of Ghana, she has contributed significantly to enhancing the department's research profile and the quality of food science education. Her work spans from developing novel sensory evaluation methods to improving local food products.   She holds a Ph.D. in Wine Chemistry and Wine Sensory Science from Charles Sturt University, Australia, a Master of Research in Food Science from the University of Strathclyde, Scotland, and a B.Sc. in Biochemistry and Food Science from the University of Ghana.   Dr. Maame Yaakwah Blay Adjei has published dozens of peer-reviewed papers in reputable journals, with her research focusing on areas such as consumer preference mapping, sensory attributes of foods, and innovative methods in sensory science. Her work on Relative Preference Mapping (RPM) has been particularly influential in the field.   Beyond her academic achievements, Dr. Adjei is passionate about industry collaboration and knowledge transfer. This shines through her role as Principal Investigator on several projects, including the "Technology Centre for quality dairy improvement in small holder dairy farming," which led to the setup of state-of-the-art laboratories and processing plants at the University of Ghana.   She is committed to professional development and serves as the Vice President/Treasurer of the African Network of Sensory Evaluation Research and as a member of various professional associations, including the Institute of Food Science and Technologists.   Maame Yaakwaah Blay Adjei on LinkedIn: https://www.linkedin.com/in/maame-yaakwaah-adjei-6159909/   To learn more about Aigora, please visit www.aigora.com

In this JCO Article Insights episode, Subodh Selukar interviews author Dr. Robert Maki on "Combining Response and Toxicity Data to Implement Project Optimus" by Maki, et al published in the Journal of Clinical Oncology September 11, 2024. TRANSCRIPT Subodh Selukar: Welcome to this episode of JCO Article Insights. This is Subodh Selukar, JCO's editorial fellow. Today, I am interviewing Dr. Robert Maki on his recent editorial, “Combining Response and Toxicity Data to Implement Project Optimus.” At the time of this recording, our guest has disclosures that are available in the manuscript and will be linked in the transcript. Dr. Maki, welcome to our podcast. Dr. Robert Maki: Hi, Subodh. It's a pleasure to be able to take part. Subodh Selukar: Yeah, thank you. So, to start us off, would you give an overview of your article? Dr. Robert Maki: Yes. Well, it's not my article, but it's just an editorial which is a commentary on an article by authors Cheng and Associates. It's called, “Exposure-Response-Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs.” That's a very technical title and so forth, and yet it's a JCO article because we think that it makes an important point that in oncological trials, we talk a lot about primary endpoints, oftentimes of overall survival or progression free survival, sometimes even just response rates, but most of the time, we don't take into account the toxicity of an agent. So, you can imagine that if a drug is relatively nontoxic, then what you see is what you get. Progression free survival could be associated with what is called some sort of so-called clinical benefit. However, if a drug is really toxic and you're just laid up on the couch all day or bed bound, or need transfusions three days a week, where is that really beneficial for the patient? But, by the same token, there's no quality of life without life itself. You have to have some sort of evidence that someone is going to be around for a longer period of time as an indication of benefit. So, these are ideas that have been played out to some degree for the better part of a quarter of a century. There's a biostatistician at MD Anderson named Peter Thall, who's one of the first people to think about this idea of combining toxicity data and response data as some sort of a combination primary endpoint for a trial. And where this comes into play for Project Optimus, this FDA initiative to come up with not just necessarily one dose or one dose and schedule, but rather a range or multiple doses and schedules for a drug based on the toxicity that's seen, is that this new paper by Dr. Cheng and colleagues provides one mechanism for doing this, for combining not just traditional clinical outcomes data, but also toxicity data. Subodh Selukar: So, you mentioned Project Optimus is an important component of all of this. So, can you tell a little bit about what Project Optimus is and maybe a little bit potentially about how Project Optimus has affected you so far? Dr. Robert Maki: I'd say it's having an effect mostly in the earlier phases of drug development. I'm not certain, but I think it was an outgrowth of some of the toxicity that was seen in some of the studies that were done over the course of the last 10 to 15 years with kinase-targeted drugs. The overall goal from the FDA Project Optimus was to work with companies, with academia, groups like ASCO and regulatory authorities, as well as patients to try and come up with dosing for everyone basically based on patient characteristics that they're focusing not just on those outcomes, such as progression, pre survival, overall survival, but also looking for quality of life and adding that into the mix in terms of how you choose a dose. So that's an effort that's been going on for the last several years now. There's been some nice articles on that from FDA on that and perhaps we could provide some links to those as well for people who are interested in some of the more introductory core information about Project Optimus. Subodh Selukar: Yeah, for sure. And so, I mean you're on the editorial board at JCO and you've written this editorial, but has Project Optimus affected your clinical research yet? Dr. Robert Maki: It's just beginning to. So, in phase 1 and 2 clinical trials, especially in phase 1, the goal is not necessarily to look for activity, but just to come up with a recommended phase 2 dose and schedule of a drug. Well, Project Optimus says, “Okay. Well, maybe there's more than one dose and schedule that should arise.” And as I was alluding to earlier, this may have arisen out of what was seen previously where a number of the multi targeted tyrosine kinase inhibitors were developed. But when you got to the phase 3 trial, it was necessary to have dose reductions in 30%, 40%, 50%, 60%, even 70% of patients in some situations. So that to me represents a drug or a development pathway for that drug that was in essence incorrect. Yes, we talk about in traditional chemotherapy of trying to get the maximum dose we can, but is that always the best thing for the patient? And we recognize that there really is a plateau usually for systemic therapies we give, that there is a limit to dose escalation even within an individual patient to try and achieve that same benefit. At some point you're just going to add toxicity. The idea is to bring some element of toxicity into the decision making for a recommended phase 2 dose and schedule or schedules in that case. Subodh Selukar: And so, building on that, so I think one advantage of these different approaches is that they might identify a single optimal dose, or maybe they'll recommend this range of doses that maximize some maybe clinical utility score combining these different aspects. In the current paradigm, it seems like probably response and toxicity are just these separate concepts that aren't typically linked together. But we typically do have a single recommended dose. But like you said, they might in subsequent trials have a lot of dose reductions and stuff like that. So how do you think about the process now where this is a single recommended dose of, but there are deviations from that recommended dose in the research process. Like you said, in subsequent trials or within a trial, maybe patients are needing their own dose reductions as well. And then separately once a product is approved, what do you think about deviating from the recommended dose for your standard clinical practice? Dr. Robert Maki: Oftentimes a work in progress. So even after phase 1, maybe having only treated 30 to 50 patients, they may be relatively homogeneous and that they have to be healthier to qualify for phase 1 trial. Once the drug is released to the whole wide world, then it becomes a different scenario, and you may have patients with poor performance status to start with. Can they still get the same benefit as the patients who got the medication in the context of a clinical trial? And it may not be the case. And I think this is where Project Optimus and the idea of giving more than one dose or schedule may be useful and say, “Okay. Well, you can give 20% less,” and what's the trade off? Maybe the drug doesn't work as well, but it is less toxic. On average, do you really lose a whole lot as a matter of a few weeks of median progression free survival? Or does the response rate really drop off as you decrease the dose intensity of your drug? One concern about having more than one dose and schedule is could you potentially be underdosing patients by the same token? Since we usually have some amount of time, at least a few weeks, to work out what's tolerable for our patient, at least the parameters of having more than one dose and schedule to choose from can be useful. Subodh Selukar: So then thinking about potentially maybe we would have a range of doses to recommend, what do you think are going to be challenges once that starts to be incorporated into clinical practice? What kind of complications do you think might happen explaining this to a patient? Dr. Robert Maki: That's a really, really good question and something that we- I think, just have a difficult time with just the regular consent form. It used to be that maybe you had a couple of information sheets on a standard drug, or if it's a clinical trial, then you'll have a relatively modest consent form that's supposed to be at, whatever, 7th, 8th, 9th grade reading level. But now you start adding this form with complex text to a consent form for a clinical trial. What are people really signing up for? They get a 40-page document, and I don't think they really understand that. So, the idea that you're trying to relate to them, pushing as hard as you can, but by the same token watching out for that toxicity, I think really does speak to those endpoints of the program, that it really can be a patient-friendly idea. Are we going to necessarily get it right every time? No. As I was mentioning previously there, if you're only treating 30 to 50 patients, you may only have partial information and you come up with some sense of dose and schedule to give. And then you move that into phase 2 and phase 3, and you may have to, you see that maybe one dose and schedule is a lot more effective as you get into a randomized portion of a phase 2 trial before you move to phase 3, for example, or you see that the toxicity is much greater with no better evidence of progression free survival. So those two scenarios could certainly rise. You can't predict them in the early phases of development of a drug, but you have to be able to react or be able to react with a solid clinical trial design that allows you to have that flexibility to make those decisions later. This is where discussion with the regulators, obviously is very important to make sure that what you're doing really still fits these guardrails, as it were, of traditional clinical trial design, or these ideas of adding in the toxicity-based information from Project Optimus. Subodh Selukar: One of the challenges in early phase trials is, like you said, we might have 30 to 50 patients at the end of the study. I think in the editorial, you mentioned that some of these newer metrics might require more and more patients. Maybe we need 30 to 50 patients on a single dose in order to have reliable understanding of these clinical utility scores. Whereas right now a sample size at a single dose might be six patients, it might even be fewer. What are your thoughts on that aspect of it? Dr. Robert Maki: That's an important point, too. When you're doing, let's say, a quick and dirty, as you might say, 3+3 design, which has very large error bars in terms of the confidence intervals around a dose and schedule compared to some of the newer Bayesian-based designs, yes, you can get a phase 1 trial quote done, especially if it's a ‘me too' sort of drug, so say, another checkpoint inhibitor, you kind of know the characteristics of those over another inhibitor of a specific kinase, you know the toxicities to expect when you block, let's say, EGF receptor. So, if you have some idea, and therefore you're able to more rapidly get to that recommended phase 2 dose from a phase 1 trial, if it ends up being a new drug, then maybe 30 to 50 patients isn't enough. And you really do need to continue that assessment of both response and toxicity as the trials move forward into phase 2 and phase 3. So, it's kind of one of those ideas of continuous process improvement that if we are going to do this, we really do need to include it, not just in early phase trials, but especially for agents that are acting through a new mechanism of action, that we look at that holistically across the drug development spectrum. And now that trials are kind of being smashed together, phase 1 and 2, now phase 2 and 3, that really increases our need to also add in the assessment of toxicity, and maybe not just on the basis of our own evaluations or lab evaluations of toxicity, but patient reported outcomes, which is something that wasn't addressed in the Cheng article and really hasn't been well addressed in clinical trials in general, I would offer. There are precious few trials that incorporate patient reported outcome data as a means to determine what's too toxic for a patient, for example. So how do we do that? As you know, we do have patient reported CTCAE clinical toxicity criteria that are based on patient reported outcomes. And wouldn't it be interesting, at the very least, as an academic project, but even more importantly, later on, to use those as the key means to determine whether a dose is too toxic or not in the development of the drug. That, to me, would be really, really interesting and kind of turns the idea of some of the data that we collect on its head. I guess, yes, we do need to collect things like liver function tests and so forth. It is one metric of toxicity of a drug. But patients have a lot of fatigue, we really do a poor job of documenting that as clinicians, and not to mention the elements that go into what that fatigue is. To be able to capture that through PROs would be another noble effort that I think has been underutilized and underappreciated in oncology clinical trials overall. Subodh Selukar: And so, what do you think are barriers to doing it now? Dr. Robert Maki: We tend to, for lack of a better term, cut and paste from what we've done before, to develop new, let's say, by patient reported outcome score or metric or worksheet for a given diagnosis. That can be hard, that takes a lot in and of itself, and perhaps has been one of the barriers that we don't have enough disease specific PROs, at least for some diagnoses. For others we do. And the fact that we do have PRO-scored CTCAE sorts of score tables, now, certainly makes it easier to validate and use these tools in clinical trials. So, I would love to see more of that, even if it ends up being secondary tertiary endpoints on phase 1, 2, and 3 trials. It's a pretty easy thing to add, even if you're doing that for the first time. Get some experience with it, and it can only help patients get through a trial or even just assessing it as part of a standard of care that will help our patients in the longer run. Subodh Selukar: Yeah. And so, thinking about other metrics of success, you mentioned a couple in your article. These aren't necessarily patient reported outcome ones, but like RECIST and RANO. I was curious. I think the Cheng article, maybe I would think about it as a general framework for combining response and toxicity together, whereas some of these other metrics are a lot more disease specific, potentially, or agent and disease specific, maybe even. Do you think that clinical research will end up settling on these metrics that are kind of increasingly specific, or do you think that there's a possibility for general frameworks? Dr. Robert Maki: Yeah, that's a tough question. I'm just trying to think of some of those patients reported outcomes. They've got kind of the general assessment ones, and then you do have ones that are more disease specific, just like we do have response criteria that are different for, let's say, lymphoma versus brain tumors versus colorectal cancer. We do have different ways of measuring those outcomes, and we all complain that those are imperfect measures. You can always find circumstances where that patient was responding, but it was called progression or vice versa. So even from these more objective tools like RECIST and the like, it's a challenging field, that's for sure. We keep going around and trying to find ways of improving those sorts of systems. But let's say, for example, you used - this is part of the reason we moved from two dimensional measurements in WHO criteria versus one dimensional RECIST - if you have two dimensions, well, you have that much more variability in the measurements of the lesion. So, it turned out that we just didn't gain anything by having those bidimensional measurements. Now, since we have the ability to measure tumors better in three dimensions, should we be using volumetric assessments? Part of it depends on the size of the tumor. If you're dealing with a tumor that's 1 cm versus 8 cm, well, then the volumetric changes, you have a lot more variability, the small ones, than the big ones. Not to mention the fact that you have shapes that are not just an ovoid mass in a lot of cancers. There's just so many pitfalls in these sorts of data. What really matters at the end of the day, one thing that's underappreciated, and again is underscored by Project Optimus, is getting back to the patient. Subodh Selukar: Your editorial made me have this one thought, and so bear with me, it's like a multi-part question. One of the reasons that we're becoming more and more interested in these alternative approaches, these clinical utility scores and everything, is that these new agents are being proposed, where there's a hypothesis that there's more complicated relationships between dose, response and toxicity. And so, 50 years ago, researchers probably didn't hypothesize that these complicated relationships were happening. They probably thought that they were more straightforward. What do you think would have happened if we had had these conversations that we're having today if we'd had them 50 years ago, what do you think would be different? Do you think that maybe we would have different therapies that kind of ended up becoming standard today? Maybe would we interpret or run studies differently today? Dr. Robert Maki: I like that question as well. Now, if we go back to the Charles Moertel studies back from the 1970s, the whole reason that we have tumor measurements as a criterion are really based on his work, where he got a series of clinicians together and he put these masses underneath a piece of rubber sheeting, and they tried to determine how well they could determine the difference between a mass that they could palpate. And this is when we came up with the idea that a partial response was a 50% decrease in the cross-sectional area of a mass. That came from that very crude but important work from about 50 years ago. And of course, that was also a time when there really wasn't any imaging. Maybe the best you would have would be x-ray tomography to look at a lung nodule or something like that. It was a little bit of a different era. We didn't know how our drugs worked very well. We had at least some biochemical reason to use chemotherapy, and we tried to leverage that. But it was always the idea of more is better, finally disproved later on, in let's say the era of breast cancer, looking at the AC combination or doxorubicin as part of a treatment for breast cancer, that there was a ceiling to the benefit of doxorubicin in the adjuvant setting. Even then, it was clear that we needed to think about dose and schedule. We also didn't have the variety of drugs that we have now, or the different metrics that we have, circulating tumor DNA or something along those lines. Those sorts of things just never existed then either. So, we need metrics that are appropriate for their time, and we have more tools to work with. I suspect that we'll have more specialization in oncology along disease lines, or even molecularly characterized subsets of diagnoses as well. All the detailed classification that we now need for a lymphoma, for example, or different flavors of triple negative breast cancer, all of those things are impacting how we even put a person on a trial. Similarly, since these patients are also going to get different classes of drugs that are relatively unique to them, there are a lot of drugs now that are available that really are only approved for one diagnosis. Then you really have to drill down pretty deeply in order to be able to focus on that clinical scenario. But I think we have the means to do so. Nonetheless, the general idea of these frameworks, again, the idea of combining response and toxicity data that can apply across essentially any cancer or neoplasm that we want to study. Subodh Selukar: Okay. So, I want to move a little bit to aspirational, like where we want to move forward now. And so I think you've talked a little bit about this so far already, but would you tell me a little bit about when you're seeing a patient, interpreting results that have been given in clinical trials, are there results, metrics, summaries of trials that you wish you could communicate to them, metrics that actually already exist but don't really get implemented? You already mentioned quality of life is something that doesn't seem to be there but are there other things that maybe quality of life might not just be collected enough yet. But are there metrics on data that we have and we just don't really report them at all? Dr. Robert Maki: That may be the case, or maybe the data end up in a secondary and tertiary publication, so they don't really become part of the lingua franca of the oncologist. I think it really speaks to just having the experience as an oncologist that you try the FDA-approved dose for medication for somebody and you run into trouble if they're, let's say, in their 80s, whereas the study population was in their 40s and their 50s with better bone marrows or better renal function on average, and things like that. So, another untested waters are geriatric oncology. What are the maximum tolerated doses when they're 80 versus when they're 40 or 50? It's a real challenge. Probably they had the most experience of that with things like prostate cancer, where we do treat largely an older population of men compared to other diagnoses, potentially. I suspect we're going to see just more specialization, just like we do with the medications. We do need more specialized assessments for those adverse events and or quality of life that will be diagnosis specific. If you have GI cancer, abdominal pain is going to be a bigger issue or obstruction sorts of questions. And the symptoms that you may have from having a tumor within the abdomen versus, let's say, another diagnosis, which may tend to give you more, let's say, lung metastases. So those little subtleties can't come out. And the toxicities of the drugs that we use in those diagnoses are also going to differ as well. So those should be kept in mind as we come up with, let's say, disease specific toxicity metrics that we want to combine with those outcome data. So, I think we're going to see more and more specialization of that over time. You have to create the tool and you've got to validate it. So, all these things will take some time. But again, people have been interested in this for a long, long time. There are any number of careers that are built around quality of life and cancer, or for example, long term survivorship in pediatric cancer patients. And all of these things can be very useful and just require our attention, both as clinical investigators as well as clinicians, when we face our patient's day to day. Subodh Selukar: And so just one last question before we close. Is there anything that we haven't had a chance to talk about that you like to share with our listeners? Dr. Robert Maki: If it's anything it's that I'm really heartened as I get older with this very large influx of new clinicians and new investigators. Oncology continues to get more interesting and more sophisticated. We need more people- we still don't have enough oncologists, even for our population here in the United States. We'll have plenty to do for a very, very long time. So, I'm excited to see a new generation of young oncologists such as yourself and the trainees that I see here, the new fellows, junior faculty who are all beginning to answer these questions, thinking about them. And as me and some of my more senior friends can help promote this kind of idea and help together to answer some of these questions. We're still trying to figure it out and there are just so many variables and clinical scenarios that we need to chase down in terms of clinical research. It is going to be an ongoing discussion and hopefully this article is just one example towards the goal again of finding the right dose for our given patient. Subodh Selukar: Thank you so much for sharing and yeah, I'm very excited to be a part of this as well. This has been Subodh Selukar interviewing Dr. Robert Maki on his recent editorial, “Combining Response and Toxicity Data to Implement Project Optimus.” Thank you for listening and stay tuned for the next episode of JCO Article Insights.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.    Dr. Robert Maki Disclosures: Consulting or Advisory Role: Deciphera, PEEL Therapeutics, Eisai, GlaxoSmithKline, Medtronic, Boehringer Ingelheim Speakers' Bureau: MJH Life Sciences  Research Funding: Amgen, Astex Pharmaceuticals, Boehringer Ingelheim, BioAtla, C4 Therapeutics, InhibRx, Regeneron, SARC: Sarcoma Alliance for Research though Collaboration, TRACON Pharma Patents, Royalties, Other Intellectual Property, Uptodate Travel, Accommodations, Expenses Company name: Stand up to Cancer, Fondazione Enrico Pallazzo  

A new week means new questions! Hope you have fun with these!Beyonce and Andre 3000 covered Amy Winehouse's Back to Black for the soundtrack to what 2013 film?According to chartable.com, what non-speaking podcast is the fifth most popular podcast in the usa as of 10 September 2024?In 1889, what replaced the Washington Monument as the world's tallest structure?Which Disney princess wore a pink dress when it wasn't being turned blue?"Portrait of the Artist as a Young Dog", was written by what Welsh poet in 1940?A compound of what metallic element, with the symbol Sr and refined from celestite, is used to create bright red fireworks?Cortland, Winesap, Jonagold and Empire are all types of what fruit?Which color is vermilion a shade of?What is the name of the fantasy world in which The Legend of Zelda series is primarily set?Though it can mean a pre-production microplastic pellet, the term nurdle can also mean a blob of what, according to a lawsuit between Colgate Palmolive and GlaxoSmithKline?Which French impressionist created the piece "After the Bath, Woman drying herself?"MusicHot Swing, Fast Talkin, Bass Walker, Dances and Dames, Ambush by Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/Don't forget to follow us on social media:Patreon – patreon.com/quizbang – Please consider supporting us on Patreon. Check out our fun extras for patrons and help us keep this podcast going. We appreciate any level of support!Website – quizbangpod.com Check out our website, it will have all the links for social media that you need and while you're there, why not go to the contact us page and submit a question!Facebook – @quizbangpodcast – we post episode links and silly lego pictures to go with our trivia questions. Enjoy the silly picture and give your best guess, we will respond to your answer the next day to give everyone a chance to guess.Instagram – Quiz Quiz Bang Bang (quizquizbangbang), we post silly lego pictures to go with our trivia questions. Enjoy the silly picture and give your best guess, we will respond to your answer the next day to give everyone a chance to guess.Twitter – @quizbangpod We want to start a fun community for our fellow trivia lovers. If you hear/think of a fun or challenging trivia question, post it to our twitter feed and we will repost it so everyone can take a stab it. Come for the trivia – stay for the trivia.Ko-Fi – ko-fi.com/quizbangpod – Keep that sweet caffeine running through our body with a Ko-Fi, power us through a late night of fact checking and editing!

Today, our special guest is Nick Fine, PhD, Principal UX Research Consultant and Strategist at Adaptavist. Nick touches on several topics, including dealing with ADHD, why user-centric design has lost its way, and the impact of economic cycles and AI on the industry. Nick also talks about the need for UX researchers to focus on insight rather than ‘depth', stating that the goal is to “get the gold and get out.” And that's just the start! Highlights include: 00:00 - Guest introduction 02:31 - Discussion on ADHD and "Chorus of Bastards" 09:15 - Nick's background in hacking and hyperfocus  17:56 - Frustration with the current state of UX 23:50 - Future of UX and AI agents 30:31 - Making yourself indispensable in UX 35:16 - Over-intellectualization of UX research 39:31 - The role of managers and leaders in UX 44:11 - Conclusion and key takeaways Who is Nick Fine, PhD Nick is a user experience researcher and designer with 20 years of experience in digital and over 12 years of experience as a practitioner. He holds a PhD and MSc in Human-Computer Interaction (HCI) and a BSc in Psychology. He successfully defended his PhD thesis in 2009, entitled “Personalizing Interaction Using User Interface Skins,” where he established a novel means for determining personality type from keyboard and mouse usage and discovered relationships between design elements (color, shape, meaning) and personality type.  By combining academic research skills and HCI knowledge with commercial UX experience, Nick has successfully delivered a number of complex and mission-critical projects, including air traffic control, financial systems, and pharmaceutical R&D. He has led UX on projects for a number of brands, including Coca-Cola, SAB Miller, Jaguar Land Rover, Bentley, EY, Novartis, GlaxoSmithKline, BT, Virgin Media, Camelot, and both the Home and Cabinet Office. Find Nick Here: Nick Fine, PhD on LinkedIn Adaptavist Website Proskin.org Website Subscribe to Brave UX Liked what you heard and want to hear more? Subscribe and support the show by leaving a review on Apple Podcasts (or wherever you listen). Apple Podcast Spotify YouTube Podbean Follow us on our other social channels for more great Brave UX content! LinkedIn Instagram The Show is hosted by Brendan Jarvis, and you can find him here: Brendan Jarvis on LinkedIn The Space InBetween Website

The Medical Messenger: Cathy Calva Cather Twenty-Seventh Episode:  Have you or anyone you love suffered an adverse effect from a prescribed or over-the-counter medication? Cathy had four loved ones affected within two years. She co-founded Parallel Testing and launched Parallel Profile™ to reduce the number of deaths (128,000/year, the fourth leading cause of death) and inpatient admissions (2.7 million/year) from adverse reactions to FDA-approved medications. Parallel Profile is available to employers interested in improving the quality of care available to their employees and eliminating preventable and wasted costs for hospital care (over $200 billion/year) and drug failures. According to a senior exec at GlaxoSmithKline, 90 percent of drugs don't work for 30 to 50 percent of the people who take them. Cathy's mission is to identify better alternatives that will work safely for each patient. She has a proven track record of developing and accelerating the growth of innovative healthcare companies that have a financial imperative to make health care more affordable, of higher quality, and more readily accessible. Please join us for a very informative conversation. Video Version: https://www.youtube.com/live/IL8o3TqsS7E?si=MjSUx2jCaO7S313b Learn more about Mark here: https://www.youtube.com/channel/UC4cXoftnMYJ7bREYG-K9eng https://www.linkedin.com/company/the-anxious-voyage/about/?viewAsMember=true https://www.facebook.com/profile.php?id=100095313165139 https://www.linkedin.com/in/markobrien/ https://www.facebook.com/MarkNelsonOBrien https://www.facebook.com/MartinTheMarlin/ mark@obriencg.com

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. This week's commercialization news includes Dupixent's success in a chronic hives study, Lilly's development of a weekly insulin shot, and BioMarin's plans for growth. The House backs a bill restricting China's role in US biotech, while Lykos CEO is set to depart after FDA rejection and layoffs. The newsletter also discusses key developments in cell therapy and offers insights on utilizing a direct-to-patient model in the healthcare industry. Various resources and upcoming events in the biopharma industry are also highlighted. Biopharma Dive provides in-depth journalism and insights into the latest news and trends shaping the biotech and pharma industries.BridgeBio has reduced its gene therapy budget after data from a trial on an adrenal gland medicine did not meet the company's investment threshold. GlaxoSmithKline has discontinued a herpes vaccine after it did not meet efficacy goals in a phase 2 study. Roivant has launched a new 'vant' focused on a hypertension drug. Centessa's sleepiness drug has shown promising results in early studies, leading to a rise in the company's shares. Additionally, Dupixent has succeeded in a chronic hives study, giving Sanofi and Regeneron a chance to resubmit their application for approval. Investors are also paying attention to Centessa's sleepiness drug. This news comes alongside updates on other pharmaceutical developments, such as Saxenda's effectiveness for children as young as 6 and Roche's expansion of R&D labs. Additionally, the newsletter covers upcoming events and resources for biopharma professionals. Biopharma Dive provides in-depth coverage of news and trends in the biotech and pharma industries, including clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.Iowa has awarded Centene's subsidiary, Iowa Total Care, a Medicaid managed care contract worth $2.8 billion. Telehealth groups are urging Congress and the White House to extend controlled substance virtual prescribing before pandemic-era flexibilities expire. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Steward Health Care received court approval to sell its three most valuable hospitals to Orlando Health for $439 million. The importance of data quality in realizing value from medical imaging data is emphasized by Enlitic. Payers are encouraged to optimize quality and grow revenue through key strategies in an upcoming webinar. Healthcare Dive provides in-depth journalism and insight into the most impactful news and trends shaping healthcare across various sectors like health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.Novo Nordisk showcased its investigational GLP-1 pill that resulted in a remarkable 13% weight loss. This comes after positive Phase I results for the pill, which analysts compared to weight loss pills being developed by Lilly and Pfizer. Expanded coverage for cardiovascular disease under Medicare could have significant implications for Novo's obesity drug, Wegovy. Analysts estimate that the expansion of Wegovy's label beyond obesity could lead to an annual Medicare spending of $145 billion. Meanwhile, GSK has abandoned the development of its herpes vaccine after disappointing Phase I/II results, and Crispr Therapeutics and Vertex Pharmaceuticals are facing challenges in making their sickle cell gene therapy profitable. Novo's other drug, Saxenda, was found to effectively and safely lower BMI in children, according to a study published in NEJM. Additionally, Lilly continues to make progress with its once-weekly insulin, while Bain has raised $3 billion for a fund supporting life sciences companies. The biopharmaceutical industry continues to see changes, with Biomarin facing challenges and Terns moving forward in the obesity spac

In this episode of the Stay Hungry Podcast, Joel and Martha discuss how to master stage presence for maximum impact. Whether you're preparing for a big talk or presenting on Zoom, they look at strategies to engage your audience, structure your talk, and deliver memorable takeaways. Joel shares his experiences, including overcoming personal challenges and honing his delivery techniques, while Martha explores the mindset needed to handle the pressure and anxiety that often come with public speaking. This episode is packed with practical tips on controlling the room's energy and ensuring your message hits home.KEY TAKEAWAYS- "Your audience will remember one key takeaway. Nail it, and you've won the room."- "If you're not prepared to challenge yourself on stage, you'll never challenge your audience."- "Preparation is everything. You can't wing a stage talk and expect it to land. Know your points, rehearse them, and deliver with confidence."- "A great stage presence isn't about gimmicks or stunts—it's about knowing your message and delivering it with authority and purpose."VALUABLE RESOURCES Stay Hungry Podcast SeriesStay Hungry Bestselling Book ABOUT THE HOST Joel StoneJoel Stone is a marketer and disciple of business strategy. After seeing the impact of the 2008 recession, he decided to take control and leave employment to set up in business for himself. He quickly built an award-winning design agency, partnering with Andy on numerous projects until they formed Codebreak in 2019.Having previously helped brands including GlaxoSmithKline, Diageo, Beta Tools, and Channel 4, Joel's work has been seen all over the world. He takes pride in applying techniques normally reserved for huge corporations to SMEs throughout the UK. Case studies of Joel's work have featured in Design Week, The Drum, and Social Media Today. InstagramFacebookLinkedIn

In this episode, Joel and Martha talk about how powerful having authority is, particularly in marketing or as a business owner. Playing to your strengths and leaning on your knowledge is key. Joel explains how to ask customers for testimonials and the massive impact that they can have on your business. VALUABLE RESOURCES Stay Hungry Podcast SeriesStay Hungry Bestselling Book ABOUT THE HOST Joel StoneJoel Stone is a marketer and disciple of business strategy. After seeing the impact of the 2008 recession, he decided to take control and leave employment to set up in business for himself. He quickly built an award-winning design agency, partnering with Andy on numerous projects until they formed Codebreak in 2019.Having previously helped brands including GlaxoSmithKline, Diageo, Beta Tools, and Channel 4, Joel's work has been seen all over the world. He takes pride in applying techniques normally reserved for huge corporations to SMEs throughout the UK. Case studies of Joel's work have featured in Design Week, The Drum, and Social Media Today. Website - https://www.codebreak.co.uk/ InstagramFacebookLinkedIn

KEY TAKEAWAYS If you know you've got things that can help people in terms of my beliefs and ways of teaching, but if you can't get your voice and message out there, then how are you meant to help that person?If you already have someone who can teach you the habits you need to improve yourself, then it's all just about applying those habits consistently to improve. VALUABLE RESOURCES Stay Hungry Podcast SeriesStay Hungry Bestselling Book ABOUT THE HOST Joel StoneJoel Stone is a marketer and disciple of business strategy. After seeing the impact of the 2008 recession, he decided to take control and leave employment to set up in business for himself. He quickly built an award-winning design agency, partnering with Andy on numerous projects until they formed Codebreak in 2019.Having previously helped brands including GlaxoSmithKline, Diageo, Beta Tools, and Channel 4, Joel's work has been seen all over the world. He takes pride in applying techniques normally reserved for huge corporations to SMEs throughout the UK. Case studies of Joel's work have featured in Design Week, The Drum, and Social Media Today. Website - https://www.codebreak.co.uk/ InstagramFacebookLinkedIn

Dr. Lillian Siu and Dr. Melvin Chua discuss the new technologies and novel therapeutics that were featured at the 2024 ASCO Breakthrough meeting. TRANSCRIPT Dr. Lillian Siu: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Lillian Siu, a medical oncologist and director of the Phase 1 Trials Program at the Princess Margaret Cancer Center in Toronto, Canada, and a professor of medicine at the University of Toronto. On today's episode, we'll be discussing key takeaways from the 2024 ASCO Breakthrough meeting in Yokohama, Japan. Joining me for this discussion is Dr. Melvin Chua, who served as the chair of Breakthrough's Program Committee. Dr. Chua is the head of the Department for Head, Neck and Thoracic Cancers in the Division of Radiation Oncology at the National Cancer Center in Singapore. Our full disclosures are available in the transcript of this episode. Dr. Chua, it's great to be speaking with you today and congratulations on a very successful Breakthrough meeting. Dr. Melvin Chua: Thanks Dr. Siu. It was really inspiring to come together again to showcase the innovative work of world-renowned experts, clinicians, researchers, med-tech pioneers, and drug developers from around the globe. Our theme this year was inclusivity and thus it was important to bring people together again in the Asia Pacific region and to foster international collaborations that are so important in advancing cancer care. This year, we invited 65 international faculty, of which 55% were from Asia. Also, importantly, we achieved approximately a 50-50 split for male to female representation. These are remarkable statistics for the meeting, and we really hope to retain this for future Breakthrough [meetings]. Dr. Lillian Siu: The meeting featured renowned keynote speakers who shared great insights on new technologies and therapies that are shaping the future of drug development and care delivery. Let's first talk about artificial intelligence and the keynote address by Dr. Andrew Trister. He gave a very interesting talk titled, “Plaiting the Golden Braid: How Artificial Intelligence Informs the Learning Health System.” What are the key messages from his talk? Dr. Melvin Chua: Couldn't agree with you more, Dr. Siu. Dr. Trister is the chief medical and scientific officer of Verily, a precision health company. He previously worked in digital health and AI at The Bill and Melinda Gates Foundation, and worked at Apple where he led clinical research and machine learning with Apple partners. But perhaps it was really his background and training as a radiation oncologist that was most pertinent as he was able to weave both the components of new AI models and the applications and pitfalls in the clinic to the audience. Dr. Trister provided a very high-level view through the history of AI and showcased the progression of the different AI models and he basically explained between deep and shallow methods as well as deductive logic versus inductive probabilistic methods. He then provided several clinical examples where these models have shown their utility in the clinic, for example, pathology and so forth. At the same time, he illustrated several pitfalls with these models. So overall, I think Dr. Trister's talk was very well received by the audience with several key messages, including the importance of [using] high-quality data as the basis of a good AI model. AI was also addressed in an Education Session that looked at Artificial Intelligence in the Cancer Clinic. And we had a panel of experts that highlighted current progress and successes with AI in the clinic, advances with AI assisted pathology for clinical research and precision medicine, large language models (LLMs) for applications in the clinic, and how we could leverage AI in precision oncology. And from this session, I had several key takeaways. Dr. Alexander Pearson [of the University of Chicago] gave a very illustrative talk on how multimodal information across clinical omics, radiological information and multi omics could be used to improve diagnostic tasks and clinical prediction across different cancers. And Dr. Joe Yeong [of Singapore General Hospital] gave a very good talk on how AI can be applied in digital pathology to accelerate research in immunology and help in the development of immunotherapies. Dr. Danielle Bitterman [of Brigham and Women's Hospital] shared very good examples of how LLMs could be used in a clinic. And I think the example that really stood out for me was how LLMs could be deployed to create responses to patient queries. And of course, the big question in the room was: How could AI eventually encapsulate compassion in their response? I think this again showcased how LLMs could really help to accelerate our clinical work going forward. And ultimately circling back to data, Dr. Caroline Chung [of MD Anderson] gave a very poignant description on the importance of data quality and how poor-quality data could eventually lead to underperforming AI models. So all in all, I think this was a great session. And what do you think, Dr. Siu? Dr. Lillian Siu: Melvin, I totally agree with you. I like all your comments and I really enjoyed the keynote as well as the session on AI in the cancer clinic chaired by Dr. Pearson. I think all these sessions were really informative. Discussions on the latest AI and machine learning, algorithms and technologies on digital pathology, LLMs and big data, as you said, really enables the attendees, especially clinicians like me, to gain a deep understanding of how AI can be translated to practical applications. Dr. Melvin Chua: Great. So, Dr. Siu, let's talk about some of the novel therapeutics that were featured at the meeting. Again, this was an important session for Breakthrough, and it's always been there. So could you share some highlights from the sessions on novel drug development from your perspective? Dr. Lillian Siu: Yes, indeed. Drug development is such an exciting aspect of this meeting. On Day 3 of the meeting, we had a keynote by Dr. Shimon Sakaguchi of Osaka University, who discussed “Targeting Regulatory T cells (Tregs) in Cancer: The Science, Trials, and Future.” And he talked about T cells, especially Treg biology, the role of Tregs in immune regulation, new developments in Treg immuno-oncology drugs, and how we can actually target Tregs to treat early cancers, etc. This talk is particularly exciting because there are now anti CCR8 antibodies in the clinic that specifically target Tregs, and some early signals of anti-tumor activities are already being observed. Dr. Sakaguchi also emphasized the importance of combination sequence and timing of drugs for the successful use of cancer immunotherapeutic agents. I also want to emphasize the Education Session that followed, titled, “The Future of Immunotherapy, New Drugs and New Ideas.” In that particular session, we heard about engineering T-cell immunity to eradicate tumors. We heard about CAR T-cell therapy in GI cancers, novel immunotherapeutic combinations, and T-cell engagers, which are bispecifics in cancer. While success with some of these immunotherapeutic modalities, such as cell therapies and T-cell engagers have been largely seen in hematological malignancies, we are beginning to observe efficacy signals in solid tumors. For example, the CAR T targeting Claudin18.2 in gastrointestinal cancers and the recently approved FDA-approved DLL3/CD3 bispecific T-cell engager, tarlatamab, in small cell lung cancer are really exciting examples. We also heard from investigators who are exploring neoadjuvant therapies in the neoadjuvant therapy session, and the key takeaway from that session is that we have growing interest in using neoadjuvant therapy or perioperative therapy. In other words, neoadjuvant plus adjuvant therapy in different cancers. In the neoadjuvant session, there were updates provided by different experts on the roles of neoadjuvant therapy in melanoma, liver cancer, bladder cancer, and nasopharyngeal cancer. Increasingly, there is randomized trial evidence to support the use of neoadjuvant therapy or perioperative immunotherapy in several cancer types with survival-based endpoints. Very exciting indeed. Dr. Melvin Chua: Indeed, I couldn't agree with you more. I think one of the things that went into designing the case-based discussions this year was that we wanted to talk about cancers that were relevant to this part of the world and hence we again showcased lung cancers, gastric cancers and melanomas, and whereby we have again perspectives from an expert from the West coupled to an expert from the East, thereby showcasing the diversity of practice around the world. The other thing that we did this year was we decided to pair the case-based discussions with the keynotes and the Education Sessions as well. For example, on Day 3, we had Dr. Sakaguchi speak on Tregs, as you mentioned. And this was followed by an in-depth session on new immunotherapies, and then followed by a case-based discussion on different melanoma cases on the role of neoadjuvant immunotherapy in this disease, and the strikingly relevance of response to prognostication. This is an important trait that we're seeing now that seems to pan out across different cancers, where we find that neoadjuvant response to combination systemic therapies and/or radiotherapy is a strong prognosticator. Dr. Lillian Siu: So, Dr. Chua, we've discussed some breakthrough treatments and promising advances in cancer care, and we've touched upon some barriers to success in cancer treatment. I would like to ask you about the keynote address by Dr. Raffaella Casolino of the World Health Organization, who spoke passionately about efforts by the WHO and its partners to build equity in cancer care. Can you share some highlights with us? Dr. Melvin Chua: Absolutely, Dr. Siu. In spite of the tremendous advances we've seen in recent years in oncology, there are still major disparities in cancer care, such as cost and access, which affect patients worldwide. I think Dr. Casolino's talk was a very nice overview whereby she showed, first of all, the WHO's impact in terms of the WHO Cancer Resolution initiative that was implemented in 2017, where through this initiative, WHO has impacted 100 countries, invested $1 billion in funds, and that has led to millions of lives saved. But she then really drilled down to some of the key examples of the focus of the WHO in terms of equalizing care in cancer. I think one which struck me was the appreciation of the disparities in the clinical trials landscape. I think it is clear that there's still a huge barrier to clinical trials between the high- and middle-income countries and the low- and middle-income countries, and the majority of clinical trials these days are industry sponsored and we really need to look at leveling the playing field in this regard. Then she highlighted the WHO's work on trying to lower the barriers to precision oncology. And I think there are several issues in that sense, but I think what the WHO has really worked hard on is promoting education for genomic medicine, where they've done several reviews with experts around the world to educate the field across the world on how we interpret and apply genomics in the clinic. So all in all, it was very interesting to hear Dr. Casolino's insights from a policy perspective, and again, this emphasizes that there's so much work to be done at the end of the day and the dialogue needs to continue. We also heard about policy, academic and industry perspectives in the context of clinical trials, and that led to a discussion on real-world evidence generation for regulatory approvals. It was very nice that we had a session on that at the end of Breakthrough 2024 (Real-World Evidence and Clinical Trials: Beyond the Ivory Tower). And in that session, we heard from Dr. Shaalan Beg [of the NIH], and Dr. Janet Dancey [of Queen's University] who represented views from academia and Dr. Hidetoshi Hayashi [of Kindai University Hospital] shared perspectives on decentralized trials. I'd like to encourage our listeners to watch these sessions if they were unable to attend. The content is very rich, and I'm sure they'll learn from it. Dr. Lillian Siu: Thank you so much, Dr. Chua. Is there anything else you would like to cover before we wrap up the podcast today? Dr. Melvin Chua: Thank you, Dr. Siu. The thing I really want to emphasize is, apart from all these Educational Sessions and having very eminent keynote speakers, one of the key points that we really want to bring out for Breakthrough is to showcase the high-quality research. This year we had 300 abstracts submitted and they were all high quality, cutting across trials, omics research, AI and technology, and eventually we selected 235 of them and we were able to showcase some of them across three oral sessions over three days. I think this is an important component of Breakthrough that we really wish to continue building upon where people are now excited to use this forum to present their work. Dr. Lillian Siu: Thank you so much, Dr. Chua. I really enjoyed our discussions today. I look forward to seeing how the Breakthrough meeting will continue to grow in future years. Dr. Melvin Chua: Thank you again, Dr. Siu. Thank you for all your leadership and efforts in making Breakthrough a successful meeting series the past few years. Dr. Lillian Siu: Thank you to our listeners for your time today. You'll find links to the session discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Lilian Siu  @lillian_siu  Dr. Melvin Chua  @DrMLChua    Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. Lillian Siu:  Leadership (Immediate family member): Treadwell Therapeutics  Stock and Other Ownership Interests (Immediate family member): Agios    Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen   Dr. Melvin Chua:  Leadership, Stock and Other Ownership Interests: Digital Life Line  Honoraria: Janssen Oncology, Varian  Consulting or Advisory Role: Janssen Oncology, Merck Sharp & Dohme, ImmunoSCAPE, Telix Pharmaceuticals, IQVIA, BeiGene  Speakers' Bureau: AstraZeneca, Bayer, Pfizer, Janssen   Research Funding: PVmed, Decipher Biosciences, EVYD Technology, MVision, BeiGene, EVYD Technology, MVision, BeiGene  Patents, Royalties, Other Intellectual Property: High Sensitivity Lateral Flow Immunoassay for Detection of Analyte in Samples (10202107837T), Singapore. (Danny Jian Hang Tng, Chua Lee Kiang Melvin, Zhang Yong, Jenny Low, Ooi Eng Eong, Soo Khee Chee)    

The Harvard geneticist sold a fake miracle pill to GlaxoSmithKline for $720,000,000, and now wants the world to believe that he has discovered a new immortality molecule. Everyone wants to live a long and healthy life. No one wants to die. The oldest scam in history is the longevity lie. The first writing recorded on Sumerian clay tablets recounts the story of Gilgamesh's failed quest to bring his friend back from the dead. The immutable fact of mortality has dogged human kind since its very beginning. And yet every age has brought with it its own crop of magicians, alchemists and scientists promising eternal life. Their pitch is always the same: everyone who came before them was a charlatan, but they have the secret sauce. The most famous longevity grifter of our age is no different. If you've ever heard a news story that a glass of red wine might make you live longer, it was because of his groundbreaking research. Harvard geneticist David Sinclair is one of the most decorated scientists on the planet. He's listed as an author on more than 500 papers, his work has been cited more than 96,000 times and he holds 50 patents. He was the editor of the journal Aging. Resume aside, David Sinclair is no different than any other health grifter throughout the ages, and great fortunes have been squandered in pursuit of his “science.” In this week's video I dive into his 25 year history of scientific mistakes, lies and fraud. I show how he used disproven research on the chemical “resveratrol” to sell a best selling book and, ultimately, a company to the pharmaceutical drug maker GlaxoSmithKlein for $720,000,000. Two years after the sale, the research was proven to not work, and Sinclair became one of the richest scientists in America. Now, ten years after that work fell apart, Sinclair is at it again selling the idea of a new immortality molecule called NMN. This video took me three weeks to put together, but it was worth the wait.

Six-time author and professional speaker Andy Lopata joins today's show to discuss the power of mentoring for both the mentor and mentee. Lopata is an acclaimed professional relationships strategist, who has worked with global clients including Paypal, GlaxoSmithKline and Brother.Connect with Andy on LinkedIn here.Order Andy & Ruth Gotian's new book, The Financial Times Guide to Mentoring, here.___________________Continue building your Competitor Mindset after today's episode by clicking HERE

Six-time author and professional speaker Andy Lopata joins today's show to discuss the power of mentoring for both the mentor and mentee. Lopata is an acclaimed professional relationships strategist, who has worked with global clients including Paypal, GlaxoSmithKline and Brother.Connect with Andy on LinkedIn here.Order Andy & Ruth Gotian's new book, The Financial Times Guide to Mentoring, here.___________________Continue building your Competitor Mindset after today's episode by clicking HERE

Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, as he shares insights into Nimbus' groundbreaking work in ultra-rare diseases, innovative corporate structure, and strategic capital management. Emphasizing bold risks, team collaboration, and strategic partnerships, Jeb shares valuable insights into biotech's challenges, opportunities, and the future of cancer therapies. Biography: Jeb Keiper, M.S., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders. Prior to joining Nimbus, Mr. Keiper served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc (NYSE: GSK)) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including the Novartis-GSK Oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Mr. Keiper was a consultant at McKinsey & Company starting in September 2000-2002, then September 2004 to 2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998. Mr. Keiper currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc., and ROME Therapeutics, Inc. Mr. Keiper received two B.S. degrees, one in Chemistry and one in Chemical Engineering, as well as an M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with the Harvard Medical School.

In this episode, I'm speaking with public health professor and environmental health scientist Dr. Yogi Hendlin about the corruption of science. Unfortunately, it's easy to be unaware of this critically important issue that negatively influences your and your family's health. This is a must-listen podcast—the information presented by Dr. Hendlin profoundly affects us all.  This podcast was initially released in April 2022 In this podcast, Dr. Hendlin and I discuss: The critical difference between REAL science vs. industry-funded science The sad fact that despite countless real-world examples of how corruption and scientific fraud cause massive harm, many people are still unaware of these issues How big industry buys the science and bribes their way to credibility by compromising the integrity of “independent” 3rd-party institutions How many industries secretly manipulate government officials to influence their regulatory processes with money, resources, or power Just how corrupt is science? And how to spot a study that might provide you with disinformation instead of trusted facts What are industrial epidemics, and how might they negatively affect ALL of us? Examples of overt corruption from companies like ExxonMobil and Glaxo-Smith-Kline who put pressure on scientists The terrible danger of hubris in officials who make policies based on industry-funded, fraudulent, and manipulated science What can we learn from the continued use of glyphosate despite the clear danger of disease that it poses? What can we do to restore the integrity of the scientific process, which is now corrupted by conflicting interests, funding, political interests, and confirmation bias? Dr. Hendlin's 3 most vital takeaways if we're going to protect our loved ones, our communities, and the planet   

Dr. Pedro Barata and Dr. Lillian Siu discuss recent advances in cancer vaccines and biomarkers, including the potential of the neoantigen and immune modulatory vaccines and the challenges surrounding cancer vaccine development. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host for the ASCO Daily News Podcast today. I'm a GU medical oncologist at the University Hospitals Seidman Cancer Center in Cleveland, Ohio, and an associate professor of medicine at Case Western Reserve University School of Medicine. I'm also an associate editor of the ASCO Educational Book. And today we'll be discussing a timely article that was recently published in the Educational Book titled, “State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.”   I'm delighted to welcome one of the article's co-authors and a world-renowned oncologist, Dr. Lillian Siu. She is a senior medical oncologist and director of the Phase 1 Program at the Princess Margaret Cancer Center and a professor of medicine at the University of Toronto.  Welcome, Dr. Siu. Dr. Lillian Siu: Thank you, Dr. Barata; it's great to be here. Dr. Pedro Barata: Wonderful. Dr. Siu will discuss new tools for cancer vaccine development, strategies for combating the immunosuppressive and tumor microenvironment. She will also address cancer vaccine guidelines and patient recruitment strategies to optimize patient selection and access to cancer vaccine trials. I should say that Dr. Siu and her co-authors also addressed this topic during an Education Session at the ASCO 2024 Annual Meeting.  Finally, our full disclosures are available in the transcript of this episode.  So again, Dr. Siu, great to be speaking with you today. I'm looking forward to our discussion.  Dr. Lillian Siu: Thank you, Dr. Barata. And before I begin, I want to acknowledge Dr. Jeffrey Weber and Dr. Inge Marie Svane, who both presented during the ASCO session you mentioned. They gave excellent presentations related to the topic of neoantigen vaccines and immune-modulatory vaccines, which we will talk about later. Dr. Pedro Barata: Wonderful. So let's get started. Cancer vaccines are among the most promising frontiers for breakthrough innovations and new strategies in the fight against cancer. The successes in vaccine development during the COVID-19 pandemic, I think, inspired further research in this area. Why do you think it's important that we harness these recent successes and technological advances to really accelerate progress in vaccine development? Dr. Lillian Siu: Absolutely. I think all of us who have lived through COVID really appreciated how important the COVID vaccine development was to all of us. It saved millions of lives. And I think we witnessed a paradigm change in drug development that none of us thought was possible, that we're able to actually bring a concept to a drug from bench to bedside within an extremely short time. That timeline is not something we would ever imagine to have happened, and it did. And I think it gives us hope that perhaps this is not just limited to the COVID vaccine; it's also extrapolatable to other therapeutics – that we can bring promising medicines to our patients in a really expedited timeline, obviously without compromising their safety.  We now know that cancer vaccines have entered a new, or maybe I should say, renewed era of promise. And it's holding promise on many fronts, Pedro, if I may. It's very exciting in the area of molecular residual disease. In other words, a setting where the cancer is treated definitively by surgery or radiation, plus adjuvant treatment. And we know some patients will relapse because we know they're at high risk. And now we also have different ways to detect these microscopic risks, such as by ctDNA, circulating tumor DNA, or biomarkers. And we know that having some therapeutic that can eradicate these cancers at such microscopic levels would be very attractive, especially with low toxicity, and I think cancer vaccine is such a candidate. And of course, we can even look further into the future of using such treatment in cancer prevention, especially in those with high risk of developing cancer, for example, those with hereditary syndromes like lynch syndrome. We're not there yet, but I think it holds that promise.   So I think, going back to your original question, if we can develop such a therapeutic that is showing promise in a very short period of time, it brings the timeline and the hope to a much shorter timeframe to really deliver to our patients in a very timely manner while safeguarding all the important parts, such as safety and tolerability. Dr. Pedro Barata: Wow, those are such important points. I couldn't agree with you, more. It's really exciting. As I think through this, and as I was reading through your piece, I was thinking it would be great if you could highlight some of the novel approaches to personalized neoantigen vaccine development that are driving progress in this space. Dr. Lillian Siu: Absolutely. And during the session, Dr. Weber spoke about the neoantigen vaccine, and he's a pioneer in this space. So I can only try to iterate some of the points he had delivered during his talk. Neoantigen is a very exciting space for immunologists because we know that tumors express these neoantigens. Many of these are unique antigens that are only expressed in tumors, so-called tumor specific antigens, that we can use as our targets, including vaccines, but not limited to vaccines. And with these altered sequences in DNA in different forms, they could be mutations and splice alterations, etc. We expect that we have modified proteins that are expressed by tumor cells, and these become targets for our drug development of vaccines. And now we can have very specific strategies, very sophisticated algorithms to figure out which neoantigens are more so called immunogenic, more likely to stimulate or activate the immune system, and they can be recognized by T cells. So leveraging this knowledge and technology, we have been able to develop especially mRNA vaccines that are deliverable to our patients through different mechanisms, for example, in lipopeptides, etc., so that we can deliver to the patients in a safe way, such that we can use it to deliver vaccines, such as in the MRD setting that I mentioned earlier, as well as in the advanced disease setting. So Dr. Weber, in his presentation, highlighted one of such vaccines that have been tested in a randomized controlled trial that is KEYNOTE-942, which randomized 157 patients to the mRNA vaccine plus pembrolizumab versus pembrolizumab alone in patients with advanced melanoma. This is a vaccine against 34 mutated neoantigens, and it showed a significant difference in the recurrence free survival with a hazard ratio of 0.56. And if you look at the 18-month relapse free survival rate, it was 78.6% versus 62.2%. Obviously, these are still fairly early data and numbers are still small. I think we would definitely look forward to the randomized phase 3 study of neoantigen vaccine in melanoma and other cancers. Dr. Pedro Barata: No, absolutely. And I agree, it's really exciting. Dr. Weber did a fantastic job going through some of that data. So let me ask you Dr. Siu, as you think about this cancer vaccine field, what are the limitations that you'd highlight when you think about cancer vaccine development? What challenges do you encounter, obstacles do you encounter?  Dr. Lillian Siu: There are many, many potential challenges. And to some extent, that's probably why cancer vaccine development has been somewhat slow for the many decades until more recently. We know first of all; the target has to be recognized. So we need immunogenic targets. So I think a lot of the effort has been put into trying to understand which antigens expressed by cancer cells are immunogenic, able to activate the immune system. They're obviously assay based methods. You're going to try and see if you can ex vivo stimulate immune cells on dishes and models, etc. But we need to also develop in silico computerized algorithms, and now with AI, I think that makes it even more tangible and exciting that we can actually understand through a large number of neoantigens or other antigens, whether we can choose the ones that are most likely going to actually stimulate T cells to be activated. And I think that is one area that there is a lot of interest in development, how to really develop ways to select out the most attractive antigens.   I would also want to highlight that the platforms, which is how we deliver the vaccine, can also pose significant challenges. For example, vaccines can be delivered using peptide-based formulation, cell-based formulation, nucleic acids and viral vectors. For some of these formulations, for example, the peptides very often are restricted to HLA. They can be rapidly degraded in the body, such that they become not really visible to the T cells anymore. Some of the formulations can be very complex. For example, the cell-base; it may need to have cells isolated from patients, cultured, stored and transported to the site of delivery, which can be very complex. For some of the nucleic acid vaccines, they can have very low transfection efficiency. It could be at risk for also having, for example, DNA vaccines integrated into the host genome. And then lastly, there's also the immune suppressive environment in the TME, such that it does not really have the effect when you give it repeatedly. It becomes attenuated and no longer effective. So these are some of the challenges associated with cancer vaccines.  Dr. Pedro Barata: Thank you for that summary. I think it's really important for folks out there, including researchers getting into this field, to be aware of potential obstacles they might encounter.  So let me ask you the opposite question as we see more compelling preclinical and clinical data emerging in this field of vaccine development, what is really exciting you the most about the newest technologies that are shaping the future of cancer vaccines, in your opinion?  Dr. Lillian Siu: I think one I want to highlight is the immune-modulatory vaccine that Dr. Svane, Dr. Inge Marie Svane had presented during the presentation at ASCO. This is a completely different strategy from the neoantigen vaccine. It targets antigens in the tumor microenvironment. And we know that in the tumor microenvironment, we have tumor cells, we have immune cells, and there are many types of cell types, including, for example, macrophages, cancer associated fibroblasts, regulatory T cells, etc. And using these particular cell types, we know that we can really develop vaccines that can stimulate the body's immune system to attenuate, to downgrade some of the negative factors in the tumor microenvironment. And this is what Dr. Svane and her group is trying to do. For example, they have an IDO vaccine that is able to actually target these antigens in the tumor microenvironment, and by that, not just suppressing the negative forces, so to speak, but also activate T cells to help attack cancer cells. I think that's a very interesting area. Very early promise has been seen already in non-small cell lung cancer in early phase trials using the immune-modulatory vaccine.  But going back to your question, what kind of advances; I mentioned earlier about having novel ways to select our antigens that are most immunogenic. There are many algorithms that are being developed, and I think we can try and leverage that kind of knowledge from artificial intelligence, machine learning. So I think that's definitely very exciting. There are also new vaccine platforms coming out. For example, there's recent data using modification of peptides, so called amphiphile vaccines, that already show very early promise in colorectal cancer, microsatellite status, colorectal cancer, as well as in pancreatic cancer in the molecular residual disease setting, where these long peptide vaccines targeting KRAS mutants together with adjuvant oligonucleotide DNA, combined together, can actually be given to patients and reduce the chance of cancer relapse in patients with resected colorectal cancer, as well as pancreatic cancer, with endpoints such as ctDNA or biomarker being downregulated. I think that's a very exciting example. Another very exciting example is cell-based vaccines that are being developed in Europe by the NKI Netherlands Cancer Institute Group, where they are looking at plasmacytoid dendritic cells that are loaded with peptides from different tumor associated antigens and then given to patients, which, again, in non-small cell lung cancer, together with pembrolizumab, has yielded very high response rate. And we will almost certainly see more trials coming out using that particular platform with the dendritic cells. So that's just some of the examples of exciting things that are happening in the vaccine field. Dr. Pedro Barata: Thank you. I'm wondering if you can share with our listeners about what really are the existing guidelines for using these new tools for discovery, methods of treatment, and perhaps optimizing patient selection to access trials.  Dr. Lillian Siu: To be honest, the latest guideline that was published from the FDA that I can find is almost 13 years ago in 2011. So I think it is time for a new guidance, or at least a draft guidance, to give some additional support and guidance in terms of what to do with these new treatments from the FDA and perhaps other regulatory agencies as well. I think we're now entering a very exciting time that cancer vaccines are no longer an ineffective therapeutic. It is now showing evidence of efficacy, not just in the advanced setting, but also in the molecular residual disease setting. There're so many questions to be answered, like how to develop these trials in early disease; what's the end point? Can we incorporate them into the neoadjuvant setting, and if so, how do we give these drugs before surgery, and do we give them maintenance after surgery? I think guidance from the regulatory authorities would be extremely helpful and informative to guide academic groups as well as the pharmaceutical sector to develop these agents in the right way. Dr. Pedro Barata: Dr. Siu, this is a fantastic summary, and we certainly are on the cusp of a new dawn of discovery and development in cancer vaccines, and super interesting to hear from you talking about it. Before letting you go, do you have any final thoughts that you'd like to share with the listeners, with all of us about this topic? Dr. Lillian Siu: I think as a drug developer like you are, I'm extremely excited because we now have yet another way to leverage the host immunity as a cancer therapeutic, and it is going to be opening a new door to combination therapy because we can imagine combining these treatments with other immunotherapeutics such as bispecific molecules such as CAR Ts and even vaccine plus vaccine combination is feasible. That came up actually during the session as a question from the audience. Can we combine neoantigen vaccines and immune-modulatory vaccines together? And both of our speakers who presented felt that it was possible. Obviously, we have to understand the sequence question and the endpoints question, but the fact that it opens a new door to combinatorial therapy, not just with immunotherapeutics, but perhaps with other therapeutics as well, antibody drug conjugates, etc., really, I think, is very exciting for this field to become further explored.  I mentioned earlier in the podcast that the whole area of cancer prevention is something that we have not been tapping into for the last decade with vaccines because it has not been very effective. Viral vaccines, of course, HPV and other vaccines targeting viruses, but targeting cancer cells is not something we have been successful using vaccines to prevent cancer from developing. I think we would be very interested to see if this will become a reality in the next decade. I think we would start off with patients with high risk of developing cancers such as, as I mentioned earlier, those with lynch syndrome, those harboring BRCA alterations, for example. Can we use these vaccines to actually prevent the cancers from developing in such high-risk individuals? I think the field is definitely open to that consideration.  Dr. Pedro Barata: Definitely. And I'd like to thank you, Dr. Siu, for sharing these great insights with us today on the ASCO Daily News Podcast. Dr. Lillian Siu: Thank you so much for your time.  Dr. Pedro Barata: And thank you to all the listeners for your time today. You'll find a link to the article discussed today in the transcript of this episode, and I encourage you to check out the 2024 ASCO Educational Book. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So again, thank you so much for your time and see you soon.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Pedro Barata  @PBarataMD  Dr. Lillian Siu  @lillian_siu   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures:    Dr. Pedro Barata: Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Dendreon  Speakers' Bureau (Inst): Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Blueearth, AVEO, Pfizer, Merck    Dr. Lillian Siu:  Leadership (Immediate family member): Treadwell Therapeutics  Stock and Other Ownership Interests (Immediate family member): Agios   Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen

Time to Reinvent? Early Bird Registration is Now Open for the September Design Your New Life in Retirement Program - Learn More ________________________ Let's face it. Retirement isn't for everyone - especially a "traditional retirement." An increasing number of people are choosing to work longer or to reinvent themselves and create their own new path forward. Mark Walton joins us to discuss his new book Unretired: How Highly Effective People Live Happily Ever After. You'll be interested in the learning about the three paths he found people are pursuing as more fulfilling alternatives to a traditional retirement. One of them may be an intriguing option for you. Mark Walton joins us from California. ________________________ Bio Mark S. Walton is a Peabody award-winning journalist and business author, Fortune 100 management consultant, and Chairman of the Center for Leadership Communication, a global executive education and communication enterprise with a focus on leadership and exceptional achievement at every stage of life. He is additionally Founder and Chairman of the Second Half Institute at the University of California, the nation's first university-based program to focus on personal leadership and career development in midlife and beyond. In addition to his most recent book, "UNRETIRED: How HIghly Effective People Live Happily Ever After" Mark is the author of "Boundless Potential: Transform Your Brain, Unleash Your Talents, Reinvent Your Work in Midlife and Beyond" was the focus of a national PBS TV special of the same name, and "Generating Buy-In: Mastering the Language of Leadership," published by the American Management Association and selected by Business Week as one of the Top 30 business books of the year. He has been a Professor of Leadership in the U.S. Navy's Advanced Management Program, at Toyota University, and at the University of North Carolina-Chapel Hill, where he taught leadership skills and strategies at the Senior Executive Institute and in the MBA and Executive MBA programs at the nationally top-ranked Kenan-Flagler Graduate Business School. As Chairman of the Center for Leadership Communication, Mark has taught extensively in corporate universities and management development programs nationwide, and has worked individually with CEO's, Division Presidents and a wide range of other senior executives and professionals at many of the world's leading organizations, including: Bank of America, Deutsche Bank, Dow Chemical Company, Duke Energy Corporation, General Electric Corporation, GlaxoSmithKline, NASA, and the United States Navy and Marine Corps. Earlier in his career, Mark was an internationally-recognized network television news anchorman, correspondent and analyst, specializing in political leadership and national affairs. A founding correspondent of Cable News Network (CNN), he served as CNN's first Chief White House Correspondent and, later, as CNN's Senior Correspondent, traveling the nation and world from CNN headquarters in Atlanta. The book 'CNN: The Inside Story' characterizes him as "one of a small group of renegades who changed the face of TV News." While at CNN, Mark was a recipient of broadcast journalism's premier honor, the coveted Peabody Award, for his role as Correspondent in CNN's live coverage, from Moscow, of the failed Soviet coup in 1991 and the subsequent fall of Communism. His reporting and writing have also been honored with The National Headliner Award, Ohio State Journalism Award, Cable Ace Award, the Gold Medal of the New York TV and Film Festival and the Silver Gavel of the American Bar Association. ________________________ For More on Mark S. Walton Unretired: How Highly Effective People Live Happily Ever After Boundless Potential: Transform Your Brain, Unleash Your Talents, Reinvent Your Work in Midlife and Beyond The Second Half Institute ________________________ Podcast Episode You May Like

In this conversation, Taylor Morgan and Jason Henkel, founder of Focus to Evolve, explore the concept of seeking truth and understanding, rather than focusing on right and wrong. Jason shares his transition from a corporate job to entrepreneurship, driven by his passion for helping others optimize their lives and find balance. He also highlights the power of using Microsoft Outlook effectively to improve productivity and emphasizes the importance of clarity and taking deliberate action, rather than getting stuck in analysis paralysis. They dive into the negative impact of constant distraction and offers practical tips for increasing productivity and finding stillness.  About Jason Henkel: An eternal truth seeker who always tries to lead with love.  Jason conducts trainings, talks, and coaching for companies,  teams, and organizations on the subject of accomplishing far more in less time while keeping wellbeing at center stage.  Renowned as the “productivity whisperer” by the US Navy SEALs, Jason Henkel is a dynamic trainer and keynote speaker focused on enabling people to achieve far more in less time, all while prioritizing well-being and mastering email management, Jason has revolutionized the work habits of tens of thousands of overwhelmed professionals globally.Having collaborated with industry giants like Wells Fargo, AkzoNobel, Northwestern Mutual, GlaxoSmithKline, Pfizer, Cintas, and many more Jason delivers immediately impactful modalities such as Flow State Engineering, Distraction Management, Biorhythm Adherence, and the Craft of the Mature 'No'. By teaching techniques like Architectural Calendaring along with Outlook & Gmail/Gsuite optimization, Jason empowers clients to eliminate busyness and burnout, replacing them with calm, deliberate, and authentic accomplishment.Knowing that rush, hurry, and habituated distractions are not prerequisites for success, Jason empowers professionals to reclaim their time and energy, making work swift, meaningful, and enjoyable. By showing healthier ways of working, Jason helps clients achieve their highest contribution while setting a new standard of balanced thriving for future generations.Resources in this episode: Contact Jason Henkel: Website: https://focustoevolve.comInstagram: https://www.instagram.com/focus_to_evolve/Facebook:  https://www.facebook.com/jason.henkel.5 Linkedin: https://www.linkedin.com/in/jasehenkel Email: jason@focustoevolve.com   Contact Taylor Morgan: Website: https://courageinthecalling.com Instagram: https://www.instagram.com/courageinthecalling.podcast Facebook: https://www.facebook.com/courageinthecalling.podcast Linkedin: https://www.linkedin.com/in/company/courageinthecalling Email: podcast@courageinthecalling.com 

Send us a Text Message.Coping with a tooth cavity is a universally dreaded experience.But what if we could detect and treat them before they cause trouble?In this week's HealthBiz Brief, Jordan Rubinson, CEO of Cavisense, elucidates how their technology detects cavities early, aiming to prevent tooth decay, safeguard oral health, and potentially reverse damage.

Ralph welcomes back Bishop William J. Barber to discuss the upcoming Poor People's Campaign March and Assembly in Washington, DC on June 29th, as well as Bishop Barber's new book "WHITE POVERTY: How Exposing Myths About Race and Class Can Reconstruct American Democracy." Then Ralph is joined by Phil Mattera from Good Jobs First to discuss their new report on corporate misbehavior, "The High Cost of Misconduct: Corporate Penalties Reach the Trillion-Dollar Mark."Bishop William Barber is President and Senior Lecturer of Repairers of the Breach, which was established to train communities in moral movement building. He is Co-chair of the Poor People's Campaign: A National Call for Moral Revival, and Founding Director and Professor at the Center for Public Theology and Public Policy at Yale Divinity School.  His new book is White Poverty: How Exposing Myths About Race and Class Can Reconstruct American Democracy.I might add, for our listeners, a lot of these social safety measures have been long enacted and are operating in Western Europe, in Canada, even in places like Taiwan and Japan—like full health insurance, and a lot of the labor rights, the absence of voter suppression, higher minimum wages. And in Western Europe, they have abolished poverty—as we know it in the United States. Ralph NaderOne thing that people are saying why they're interested [in the Poor People's Campaign] is because this is not just a gathering of a day, and it's not just a gathering for a few high-profile people to speak. The messengers are going to be the impacted people, and many of the people are committing to the larger effort of mobilizing these poor low wealth voters.Bishop William BarberIt's not just “saving the democracy”, Ralph. It's what kind of democracy do we want to save?Bishop William BarberWe see the kindredness of issues and oppression— that if these bodies can come together and unite, not by ignoring the issue of race, but by dealing with it and dealing with race and class together and recognizing the power that they have together, there can be some real fundamental change.Bishop William BarberPhil Mattera serves as Violation Tracker Project Director and Corporate Research Project Director at Good Jobs First. Mr. Mattera is a licensed private investigator; author of four books on business, labor and economics; and a long-time member of the National Writers Union. His blog on corporate research and corporate misbehavior is the Dirt Diggers Digest, and has written more than 70 critical company profiles for the Corporate Rap Sheets section of the Corporate Research Project website. He is co-author, with Siobhan Standaert, of the new report “The High Cost of Misconduct: Corporate Penalties Reach the Trillion-Dollar Mark”. This is a big problem with the Justice Department—it has this addiction to leniency agreements and it wants to give companies an opportunity not to have to plead guilty when there actually are criminal cases brought against them. So they offer them these strange deals—non-prosecution and deferred-prosecution agreements. And the theory is that the company is going to be so shaken up by the possibility of a criminal charge that they'll clean up their act, and they'll never do bad things again. But what we've seen over and over again is the companies get the leniency agreement and then they break the rules again. And sometimes the Justice Department responds by giving them another leniency agreement. So it turns the whole process into a farce. Phil MatteraWe're always interested in more transparency about both the misconduct and about enforcement actions. We feel that there's no justification for agencies to ever keep this information secret…I think there needs to be more pressure on companies, particularly high profile companies that have been involved in these offenses. A lot of companies seem to think that they pay their penalty, they just move on, and it's as if it's as if it never happened.Phil MatteraIn Case You Haven't Heard with Francesco DeSantisNews 6/5/241.  In Mexico, Claudia Sheinbaum has been elected president in a landslide. Sheinbaum is the hand-picked successor of Mexican president Andrés Manuel López Obrador, or AMLO, who is termed out but leaves office with an 80% approval rating, per Gallup. Sheinbaum is Mexico's first woman president; she is also the country's first Jewish president. In addition to years of service in government, Sheinbaum is an accomplished climate scientist who worked with the Intergovernmental Panel on Climate Change. During her campaign, Sheinbaum published a list of 100 commitments she will pursue as president. Front and center among these are climate-related goals. Sustainability magazine reports “[Sheinbaum] has committed to investing more than…$13 billion in new energy projects by 2030, focusing on wind and solar power generation and modernising hydroelectric facilities.” We urge the U.S. government to follow suit.2. Stacy Gilbert, a senior civil military adviser for the U.S. State Department, resigned last Tuesday, alleging that “The state department falsified a report…to absolve Israel of responsibility for blocking humanitarian aid flows into Gaza,” per the Guardian. Gilbert claims “that report's conclusion went against the overwhelming view of state department experts who were consulted.” As the article notes, this report was a high stakes affair. Had the State Department found that the Israeli government had violated international humanitarian law, and linked those violations to U.S.-supplied weapons, there would have been serious consequences regarding the legality of American military support. In addition to Gilbert, “Alexander Smith, a contractor for the US Agency for International Development… resigned on Monday…[saying] he was given a choice between resignation and dismissal after preparing a presentation on maternal and child mortality among Palestinians.”3. Per the Jeruslam Post, “South African International Relations and Cooperation Minister Naledi Pandor affirmed…that the United States would be next if the International Criminal Court (ICC) is allowed to prosecute Israeli leadership.” Pandor “went on to claim that nations and officials who provide military and financial assistance for Israel's war against Hamas in Gaza ‘will be liable for prosecution…' [and]…noted that a group of 140 international lawyers are currently working on a class action suit against non-Israelis, including South Africans, who have been serving in Israel's military.” International law experts like Bruce Fein have previously warned that the United States' material support for Israel during this genocidal campaign makes this country a co-belligerent in this war and therefore liable for prosecution by the ICC.4. Liberal Israeli news outlet Haaretz has published a shocking report related to the recent revelations concerning Mossad's intimidation campaign against the ICC. According to Haaretz's report, the paper was “about to publish details of the affair” in 2022, when “security officials thwarted it.” Al Jazeera adds that the Haaretz journalist behind the story, Gur Megiddo was told during his meeting with an Israeli security official, that if he published, he “would suffer the consequences and get to know the interrogation rooms of the Israeli security authorities from the inside.” This story highlights how deeply Israel has descended into authoritarianism, seeking to bully and silence not only international watchdogs, but their own domestic journalists.5. Prem Thakker of the Intercept is out with an outrageous story of censorship at elite law reviews. According to Mr. Thakker, “In November, human rights lawyer Rabea Eghbariah was set to be the first Palestinian published in the Harvard Law Review. Then his essay was killed. [On June 3rd], he became the first [Palestinian published] in the Columbia Law Review. Then the Board of Directors took the whole site down.” As I write this, the Columbia Law Review website still says it is “under maintenance.”6. Lauren Kaori Gurley, Labor Reporter at the Washington Post, reports “16 [thousand] academic workers at UC San Diego, UC Santa Barbara, and UC Irvine will [go on] strike…according to their union… They will join 15 [thousand] workers already on strike at UCLA, UC Santa Cruz, and UC Davis over the university's response to pro-Palestine protests on campus.” We commend these academic workers for leveraging their most powerful tool – their labor – on behalf of their fellow students and those suffering in Palestine.7. More Perfect Union reports “The FBI has raided landlord giant Cortland Management over algorithmic price-fixing collusion. Cortland is allegedly part of a bigger conspiracy coordinated by software firm RealPage to raise rents across the country through price-fixing and keeping apartments empty.” Paired with the recent oil price fixing lawsuit and the announcement from retailers that they are lowering prices on many consumer goods, a new picture of inflation is starting to emerge – one that has less to do with macroeconomic reality and more to do with plain old corporate greed.8. Vermont has passed a new law making it the first state in the nation to demand that “fossil fuel companies…pay a share of the damage caused by climate change,” per AP. Per this report, “Under the legislation, the Vermont state treasurer, in consultation with the Agency of Natural Resources, would provide a report…on the total cost to Vermonters and the state from the emission of greenhouse gases from Jan. 1, 1995, to Dec. 31, 2024… [looking] at the effects on public health, natural resources, agriculture, economic development, housing and other areas.” Paul Burns of the Vermont Public Interest Research Group said of the law “For too long, giant fossil fuel companies have knowingly lit the match of climate disruption without being required to do a thing to put out the fire…Finally, maybe for the first time anywhere, Vermont is going to hold the companies most responsible for climate-driven floods, fires and heat waves financially accountable for a fair share of the damages they've caused.”9. Following months of pressure and a probe led by Senator Bernie Sanders, Boehringer – one of the largest producers of inhalers – has announced they will cap out of pocket costs for the lifesaving devices at $35, per Common Dreams. Boehringer used to charge as much as $500 for an inhaler in the U.S., while the same product sold in France for just $7. Sanders, continuing this crusade, said "We look forward to AstraZeneca moving in the same direction…in the next few weeks, and to GlaxoSmithKline following suit in the coming months,” and added “We are waiting on word from Teva, the fourth major inhaler manufacturer, as to how they will proceed."10. Finally, the Justice Department has unsealed an indictment charging Bill Guan, the Chief Financial Officer of the Epoch Times newspaper with “participating in a transnational scheme to launder at least…$67 million of illegally obtained funds.” The Epoch Times is the mouthpiece of a bizarre anti-Communist Chinese cult known as the Falun Gong, famous for their outlandish beliefs such as that proper mastery of qigong can be “used to develop the ability to fly, to move objects by telekinesis and to heal diseases,” per the New York Times. The Falun Gong is also the entity behind the Shen Yun performances and their ubiquitous billboards. In recent years, the Epoch Times has gone all-in on Right-wing propaganda and fake news, with close ties to the Trump White House and campaign, as the Guardian has detailed. We urge the Justice Department to pursue this indictment to the hilt and shut down this rag that has become a cancer within our republic.This has been Francesco DeSantis, with In Case You Haven't Heard. Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

My guest today is author of a few good books including, How to work with almost anyone, How to Begin, The Advice Trap and the one we all know and love, The Coaching Habit, Say Less, Ask More & Change the Way You Lead Forever. Michael Bungay Stanier has a gift for distilling big, complex ideas into practical, accessible knowledge for everyday people that helps them be a force for good.His books have sold over a million copies, with The Coaching Habit topping The Wall Street Journal bestseller list. MBS has been featured on the blogs and social media platforms of thought leaders including Seth Godin, Tim Ferriss, and Brené Brown, and has appeared on ABC, BBC, CBC, Ted.com, and innumerable podcasts--as well as in notable publications including the Harvard Business Review, Forbes, Inc., and Fast Company. MBS is the founder of Box of Crayons, a learning and development company, that helps organizations move from advice-driven action to curiosity-led transformation. They have trained more than half a million people for clients including Microsoft, Salesforce, TELUS, and Gucci. Before establishing Box of Crayons, MBS's accomplishments included publishing an academic article on James Joyce and a Harlequin-esque short story; playing small roles in helping invent Pizza Hut's Stuffed Crust pizza and creating "one of the worst single-malt whiskies in existence"; and spending 20 minutes writing what has remained GlaxoSmithKline's global vision for more than 20 years. A former Rhodes Scholar, MBS is an Australian who now lives in Toronto, Canada. This show is dedicated to Michael's journey, this conversation is what we make it. This is Counsel Culture. Learn more at www.ericbrooker.com | www.mbs.works | www.bestpossiblerelationship.com